Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)
Phase: PHASE4
Conditions: Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
Sponsor: Celgene

',6&/2685(
5('$&7('35272&2/$0(1'0(17
$%,16&/
6$)(7<$1'()),&$&<2)QDE3$&/,7$;(/$%5$;$1(,1&20%,1$7,21
:,7+&$5%23/$7,1$6),567/,1(75($70(17,1(/'(5/<68%-(&76
:,7+$'9$1&('12160$//&(///81*&$1&(516&/&$3+$6(,9
5$1'20,=('23(1/$%(/08/7,&(17(5678'<$%281'

7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW\RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHUKDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RUUHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFHUWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HOJHQH¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x
5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQLQJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x
$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGXDOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x
$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLRQDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\VHV
x
&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFWOLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNVLQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x
,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFWHGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQVSUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVSURWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODELOLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1(35235,(7$5<,1)250$7,21
1
6
(,9
(,9


RWEHVKDUHG
RWEHVKDUHG
FKHUVDQGSD
KHUVDQ
JXO
JXODWLRQVUH
DWLRQVU
DORUF
RUFRQWUDF
RQWUDF
WRFHUWDLQSD
FHUWDLQS
DLQLQIRUPDW
LQLQIRUPDW
&HOJHQH¶VF
&HOJHQH¶V
SULQFLSOHV
SULQFLSOHV
H\ VSDFHPD
VSDFHPD
ILILFDWLRQRIL
FDWLRQRIL
QFRQILGHQ
FRQILG
WLD
WL
DLQLGHQWLILD
LQLGHQWLI
OVRPD\FRQ
OVRPD\FRQ
LVJHQHUDWLQ
VJHQHUDWL
DWWDFKPHQWV
WWDFKPHQ
RIWKHUHSR
RIWKHUH
W&HOJHQHY
&HOJHQHY
KDWLQIRUPDW
KDWLQIRUPD
DERXWRXUY
DERXWRXU
RQDERXW&H
DERXW&H
QGDWKWWSZ
QGDWKWWSZ

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
1
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
TITLE PAGE
SAFETY AND EFFICACY OF nab-PACLITAXEL 
(ABRAXANE®) IN COMBINATION WITH 
CARBOPLATIN AS FIRST LINE TREATMENT IN 
ELDERLY SUBJECTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC): A PHASE IV, 
RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY
(ABOUND.70+)
STUDY DRUG
nab-Paclitaxel (Abraxane®)
PROTOCOL NUMBER:
ABI-007-NSCL-005
ORIGINAL DATE FINAL:
06 Mar 2014
AMENDMENT 1 DATE FINAL:
09 Apr 2014
EudraCT NUMBER:
Not applicable
IND NUMBER:
114882
SPONSOR NAME / ADDRESS:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board. The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
provided to yo
provided to yo
aff, and ethic
f, and ethic
t is regarded 
t is regarded
35235,(7$5<,1)250$7,21
L
TUDY
TUDY
el (
l (Abraxa
Abraxa
NSCL
SC -005
00
ar
ar 2014
20
9 Apr
Apr 2014
20
Not app
Not ap
1148
148
ay not be disc
y not be disc
Persons to wh
ersons to wh
35
35
(/
(/
(/
(/
(/
(/
(/*

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
2
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: 
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
Phone:
E-mail:
Contact Information:
Name:
Title:
Address: 
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
Phone:
E-mail:
Note: The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24 Hour Global Emergency Contact Call Center: 
&(/*(1(
Global Em
Global Em
( 352
52
global eme
global em
Clinical R
linical R
235,(7$
7$
35
23
$5<,1)250$7,21
0
50
25
)2
,1
<
$5
(
(1
7$5
523

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
3
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head
dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.
&(/*(1(35235,(7$5<,1)
1)
1)250$7,21
0$
0$
50
ntent to be
ntent to b
1)

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
4
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
0$
0$
50
s study
s study at m
at
y
, informed 
nformed 
ocedures, in
edures, i
Good Clin
Good C
ct of clinica
of clinic
$5
$5

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
5
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:
 
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
&(/*(1(35235,(7$5<,1)2
omply
omply wi
y
th
i
e throughou
 througho
7$5
250$7,21
0$
0$
50
)25

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
6
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
PROTOCOL SUMMARY
Study Title
Safety and efficacy of nab-paclitaxel (Abraxane) in combination with carboplatin as first line 
treatment in elderly subjects with advanced non-small cell lung cancer (NSCLC): A Phase IV, 
randomized, open-label, multicenter study (Abound.70+).
Indication
First-line treatment of advanced NSCLC in elderly subjects.
Objectives
Primary
!
To assess the safety and tolerability of continuous weekly versus weekly times three 
with one-week break nab-paclitaxel (Abraxane) in combination with carboplatin as 
first-line treatment for advanced NSCLC in elderly subjects (≥ 70 years old).
Secondary 
!
To evaluate the efficacy of nab-paclitaxel in combination with carboplatin in elderly 
subjects with advanced NSCLC.
Exploratory 
!
To assess healthcare resource utilization for the two nab-paclitaxel treatment arms.
!
To assess the Lung Cancer Symptom Scale (LCSS) and EuroQol Group 5-Dimension 
Self-Report Questionnaire score (EQ-5D) for the two nab-paclitaxel treatment arms.
!
 
 
!
 
Study Design
This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus 
weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-
line treatment in elderly subjects (≥ 70 years old) with advanced NSCLC who are not candidates 
for curative surgery or radiation therapy. Approximately 284 subjects with locally advanced or 
metastatic NSCLC will be randomized in this study to receive nab-paclitaxel in combination 
with carboplatin and will be randomized 1:1 into one of the two treatment arms prior to starting 
first dose of study drug. Randomization will be centralized and stratified by Eastern Cooperative 
Oncology Group (ECOG) performance status (0 versus 1, see Appendix A) and histology 
(squamous cell carcinoma versus non-squamous cell carcinoma).
The study will consist of a 28-day Screening Period, a Treatment Period and a Follow-up Period.  
 randomize
randomize
ree
ree wi
with
th
i
o
h
t inin elelderly
derly
ve surgery
surgery o
y
atitic NSCLC
SCLC
h carboplat
h carboplati
rst dose of
rst dose of
Onco
On
lolog
quam
q am
235,(7$5<,1)250$7,21
weekly t
weekly tim
i
n wi
n with
th
i
carb
carb
h
s (≥ 70 y
≥ 70 yea
e
natatioion wi
n 
th
i
fo
for the
r the tw
tw
m Scale (LC
m Scale (L
(EQ
(EQ-5D)
5D) fo
fo
235
2
52
352

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
7
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
The Screening Period for eligibility determination begins upon subject written informed consent.  
All screening assessments must be completed within 28 days prior to first dose of study drug.
The Treatment Period begins with the first dose of study drug as described in Section 8.  Subjects 
will receive one of the following treatments based on the randomization assignment:
Arm A (21-day treatment cycle):
!
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, 
and 15 of each 21-day treatment cycle,
!
Carboplatin area under the curve (AUC) = 6 mg*min/mL IV on Day 1 of each 21-day 
treatment cycle after completion of nab-paclitaxel infusion.
Arm B (21-day treatment followed by one-week break cycle, 28-day duration):
!
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, 
and 15 of each 21-day treatment  followed by one-week break cycle (i.e. every 28 
days),
!
Carboplatin AUC = 6 mg*min/mL IV on Day 1 of each 21-day treatment followed by 
one-week break cycle (i.e. every 28 days), after completion of nab-paclitaxel 
infusion. 
No additional anticancer agents are allowed during study treatment.  All supportive care
(including but not limited to growth factors, antiemetics, analgesics, zolendronic acid, 
denosumab) is permitted as per the investigator’s discretion and should be administered 
according to local institutional practice. Subjects will continue treatment until disease 
progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of 
consent, in accordance with local standard of care.
Tumor evaluations will be assessed by the investigative sites and response will be determined 
according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1
(v1.1) (Eisenhauer, 2009).
Local laboratory test data for absolute neutrophil count (ANC), platelet count, hemoglobin and 
serum creatinine will be collected in the electronic case report forms (eCRFs). All other 
laboratory test data, except those mentioned above, will not be collected routinely in the eCRF. 
All abnormal and clinically significant laboratory test results will be reported as adverse events 
(AEs) or serious adverse events (SAEs), and the specific associated laboratory parameter(s) 
should be recorded on the laboratory assessments eCRF. Local safety laboratory data will also be 
the primary guide for eligibility and subject management. In addition, test results for tumor 
mutational status of genes including but not limited to EGFR, ALK, and KRAS will be collected 
and recorded on eCRF if these tests have been performed locally for routine diagnosis.  
All subjects who discontinue from treatment for any reason other than withdrawal of consent or
lost to follow-up will enter the Follow-up Period. It will consist of a visit 28 days after treatment 
discontinuation. Thereafter, subjects will be followed for survival approximately every 90 days 
(or when they are seen for routine care) by phone call or chart review for documentation of last 
contact for up to 6 months after the last subject is randomized or 192 progression-free survival 
(PFS) events have been observed, whichever comes later.
&(/*(1(35235,(7$5<,1)250$7,21
1-day
day
s on Day
s on Days 1
cle
cle (i(i.e. ev
.e. ev
-day
day treat
trea
etioi n of 
of nab
na
eatm
atment
ent.  . A
analges
analgesics
i
retion
retion and 
and 
will
will cont
ontinu
xicit
xicity,y, deat
de
f care.
f care.
he invest
he investig
teri
teria in So
a in
absolute neu
bsolute n
llected in th
ected in 
ept those m
ept those 
ically signi
ically sig
dverse even
dverse even
ded on the l
ded on the 
guide for el
guide for el
status of 
status of 
orded on e
orded on e
subjects w
subjects w
ost to foll
st to foll
didisconti
scont
w

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
8
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Those subjects entering the Follow-up Period without documented progression will continue to 
have computed tomography (CT) scans in accordance with standard of care (at least every 90 
days) until documented progression of disease, withdrawal of consent, lost to follow-up, death or 
study closure. 
Study Population
Male and female subjects ≥ 70 years of age, with locally advanced or metastatic NSCLC who 
have not received chemotherapy for their advanced disease and are not candidates for curative 
surgery or radiation therapy, will be eligible for this study.
Length of Study
The enrollment of 284 subjects on this study will take approximately 24 months. The total length 
of this Phase IV study with follow-up is estimated to be approximately 3 years.  
Study Treatments
nab-Paclitaxel and carboplatin are designated as non-investigational products and investigative 
sites will use standard of care (commercially available) product via routine prescription.
The preparation for IV administration procedures for nab-paclitaxel and carboplatin should be 
followed in accordance with the approved Prescribing Information for each drug.
Statistical Methods
Approximately 284 subjects will be randomized in a 1:1 ratio to one of two treatment arms 
(approximately 142 per arm).  Arm A will receive nab-paclitaxel 100 mg/m2 administered on 
Days 1, 8 and 15 in combination with carboplatin AUC = 6 mg*min/mL on Day 1 of each 21-
day treatment cycle, and Arm B will receive the same treatment in the same schedule as that of 
Arm A during the first 21 days, followed by a one-week break prior to the start of the next cycle
(28-day duration).  
Randomization will be stratified by ECOG performance status (0 versus 1) and histology 
(squamous cell carcinoma versus non-squamous cell carcinoma).
The primary objective of this study is to assess the safety and tolerability of the two treatment 
arms for first-line treatment of locally advanced or metastatic NSCLC in elderly subjects ( ≥ 70 
years old).  The primary study endpoint, correspondingly, is the percentage of subjects with 
either peripheral neuropathy of Grade ≥2 or myelosuppression AEs Grade ≥3 based on the local
laboratory values for ANC, platelet count, and hemoglobin, assessed using National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4.0). 
The peripheral neuropathy events will be identified from the clinical AE dataset using the 
Standardised MedDRA Queries (SMQs). For the purpose of this protocol, this endpoint will be 
referred to as the percentage of subjects with Grade ≥2 peripheral neuropathy or Grade ≥3 
myelosuppression laboratory adverse events.  
The study is designed to detect a difference of 16 percentage points between the 2 treatment arms
with respect to the primary safety endpoint with 80% power and a Type-I error rate of 5% (two-
sided), assuming 139 of the 142 randomized subjects per arm will receive at least one dose of 
study drug and the percentage of the treated subjects with the AEs specified above is 73% for 
Arm A.
&(/*(1(35235,(7$5<,1)250$7,21
total length
total lengt
uct
ucts and inv
and inv
tine
ine prescri
presc
el and carbo
l and carb
on fo
for each
 ratio to
atio to on
o
b-paclitaxe
paclita
AUC = 6 m
AUC = 6
e same trea
same tre
a one-
on
wee
wee
ECOG perf
ECOG pe
non
on-squam
squa
study
study i
y s to
s to
t of 
of lolocally
cally
y study
stu
endp
en
ropathy
opathy of
o
y
G
f
for ANC, p
or ANC, p
Common T
Commo
ral
ral neuropa
neuropa
l
sed MedDR
d MedD
d to as the 
d to as the 
elosuppress
losuppress
The study
The study
wi
with
th
i
res
re
h
d

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
9
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
A non-binding interim analysis for futility with the primary safety endpoint will be conducted 
when approximately a total of 139 treated subjects have either completed 6 months of study 
treatment or discontinued from the study due to progression, adverse events, deaths, lost to 
follow up, or other reasons. The study may be stopped early for futility if the treatment 
difference is between ± 0.4%, given the interim analysis is performed at 50% information 
fraction. 
Overview of Safety Assessment
The treated population, which includes all randomized subjects who received at least one dose of 
study drug, will be the analysis population for all safety analyses.  
The primary study endpoint (a composite safety endpoint) will be the percentage of subjects with 
Grade ≥2 peripheral neuropathy or Grade ≥3 myelosuppression laboratory adverse events.  
The null (Ho) and alternative (Ha) hypotheses for this endpoint are as follows, where P is the rate 
of the AEs described for the primary safety endpoint: 
Ho:  P Arm B = P Arm A
Ha:  P Arm B ≠ P Arm A
The AE rate of the primary study endpoint will be summarized within each treatment arm by 
descriptive statistics.  The treatment difference in the AE rate will be analyzed using a Mantel-
Haenszel Chi-square test with ECOG performance status (0 versus 1) and histology (squamous 
cell carcinoma versus non-squamous cell carcinoma) as the stratification factors.  The ratio of the 
AE rates will be summarized along with the two-sided 95% confidence interval (CI). 
Adverse events will be analyzed in terms of treatment-emergent adverse events (TEAEs), 
defined as any AE or SAE that begins or worsens in grade on or after the start of the study drug
through 28 days after the last dose of the study drug. Additionally, any SAE that occurs beyond 
this period of observation and is assessed by the investigator as related to the study drug, will be 
reported and analyzed.  
Treatment-emergent adverse events will be summarized by treatment arm by system organ class
and preferred term. Grade 3 or higher TEAEs, SAEs, TEAEs leading to dose modification 
(reduction, delay not given, and interruption), TEAEs leading to treatment discontinuation, and 
TEAEs with an outcome of death will be summarized by treatment arm. Adverse events of 
special interest of the nab-paclitaxel and carboplatin combination identified in previous studies
in a similar population will be summarized in the same manner.
In order to investigate the maximal degree of myelosuppression, ANC, platelet count, and 
hemoglobin will be summarized by the most severe grade in each treatment cycle and by the 
most severe grade during the study using NCI CTCAE v4.0. 
Overview of Efficacy Assessment
All efficacy analyses will be based on the intent-to-treat (ITT) population, which includes all 
randomized subjects regardless of whether they receive any study drugs or have any efficacy 
assessments performed.  
&(/*(1(35235,(7$5<,1)250$7,21
of 
of
bjects
bjects wi
with
th
i
events.
events.
here
here P is t
i
d wit
d within ea
hin 
ate will be 
e will be
us (0 0 versu
versu
as the stra
as the s
ided 95% 
ided 95%
eatment
eatment-e
worsens in g
orsens in g
e study
study dru
dr
y
ssed by the
ssed by t
events will 
events will
3 or higher
or highe
ven, and
ven, and int
i
me of
e of deat
de
f
the
he nab
nab-pa
pa
pulat
pulatioion wil
n w
invest
nvest
i
igate
igate
bin will be
will b
severe grad
severe gr
Overview o
Overview o
&(
All
All effic
effi
d

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
10
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Progression-free Survival (PFS) based on investigator’s assessment of the subject’s radiologic 
response using RECIST v1.1 guidelines, Overall Response Rate (ORR), and Overall Survival 
(OS) are the key efficacy endpoints.  Since the primary research interest of this study is to 
evaluate the relative safety and toxicities of the two treatment arms, the sample size was
calculated based on the primary safety endpoint, the percentage of subjects with Grade ≥2
peripheral neuropathy or Grade ≥3 myelosuppression laboratory adverse events.  Consequently, 
a statistically non-significant treatment difference in PFS, ORR or OS could simply be a function 
of the sample size and/or the lack of statistical power. Therefore, the assessments of treatment 
differences in PFS and OS will be based on the hazard ratios and in ORR, the ratio of response 
rates, and the corresponding 95% confidence intervals. P-values for between-group comparisons 
will be provided to indicate the strength of association only.  No multiplicity adjustment with the 
Type-I error rate will be made. 
Progression-free survival is defined as the time from the randomization date to the start of 
disease progression or subject death from any cause, whichever occurs first. Subjects who do not 
have disease progression or have not died as of the data cutoff date for the statistical analysis will 
be censored at the time of the last radiologic assessment prior to the data cutoff date. Rules for 
censoring for missing visits and start of anticancer treatment are provided in Section 10. 
Progression-free survival will be summarized using the Kaplan-Meier method and by median 
PFS time (including two-sided 95% confidence interval [CI]) for each treatment arm along with 
the hazard ratio (including two-sided 95% CI) between treatment arms. The Kaplan-Meier curve 
for PFS will be presented graphically for each treatment arm. To illustrate the strength of 
association, the p-value for treatment difference in the curves will be reported from a stratified 
log-rank test with ECOG performance status (0 versus 1) and histology (squamous versus non-
squamous cell carcinoma) as the stratification factors.  
Of note, if recruitment is complete in 24 months, assuming that approximately 67% of the 284 
subjects randomized will experience a PFS event (approximately 192 PFS events total) within 28
months from first subject randomized, there is 73% power to detect a hazard ratio (HR) of 0.69 
for PFS improvement with Arm B over Arm A and an overall Type-I error rate of 5% (two-
sided).  Assuming an exponential distribution with a median time to PFS of 5.8 months for Arm 
A and proportional hazards, a hazard ratio of 0.69 constitutes a 2.6 months improvement for Arm 
B. 
Overall response rate (percent of subjects who had a radiologic complete or partial response 
according to the investigator’s assessment of response based on RECIST v1.1 guidelines) and 
OS also will be assessed by descriptive statistics with the associated 95% CIs.  P-values from a 
Chi-square test and a stratified log-rank test will be provided to indicate the strength of 
association for the treatment differences in ORR and OS, respectively.  
The analyses of the safety and efficacy endpoints for the clinical study report will be performed 
after ~192 PFS events have been observed.
se 
arison
arisons s 
nt wi
t with
th
i
the
the
h
he start of 
he start of 
Subjects wh
Subjects wh
statist
statistical a
ical a
a cutoff d
a cutoff dat
vided in Se
ded in Se
Meier m
ie
eth
eth
for each tr
or each 
f
atment
ment arm
arm
arm
rm. To il
. To 
he curves w
e curves
ersus 1
ersus ) and
an
actors.
actors.
ontnths, assu
hs, assu
PFS event (
FS event
d, there is 7
d, there i
over Arm
over Arm
al 
al distribut
distribut
a hazard ra
a hazard
 (percent o
(percent 
vest
vestigator
igator
 assessed b
assessed
est and a st
est and a s
n fo
for the tr
the tr
analyses of 
analyses o
er ~192
r ~192 PF
PF

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
11
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................18
1.1.
Non-small Cell Lung Cancer ..................................................................................18
1.2.
nab-Paclitaxel in NSCLC .......................................................................................19
1.3.
Rationale for Further Study of nab-Paclitaxel as First-line Treatment in 
Elderly Subjects with Advanced NSCLC................................................................20
2.
STUDY OBJECTIVES...........................................................................................22
2.1.
Primary Objectives .................................................................................................22
2.2.
Secondary Objective...............................................................................................22
2.3.
Exploratory Objectives ...........................................................................................22
3.
STUDY ENDPOINTS............................................................................................23
3.1.
Primary Endpoint....................................................................................................23
3.2.
Secondary Endpoints ..............................................................................................23
3.2.1.
Safety.....................................................................................................................23
3.2.2.
Efficacy..................................................................................................................23
3.3.
Exploratory Endpoints............................................................................................23
4.
OVERALL STUDY DESIGN ................................................................................24
4.1.
Study Design ..........................................................................................................24
4.1.1.
Follow-up Period....................................................................................................25
4.2.
Study Design Rationale ..........................................................................................25
4.3.
Study Duration .......................................................................................................27
4.4.
End of Trial ............................................................................................................27
5.
TABLE OF EVENTS.............................................................................................28
6.
PROCEDURES......................................................................................................31
6.1.
Medical History......................................................................................................31
6.2.
Prior and Concomitant Medications/Procedures......................................................31
6.3.
Computed Tomography (CT) Scan of Complete Chest (including base of 
neck and adrenal glands).........................................................................................31
6.4.
Weight....................................................................................................................32
6.5.
Body Surface Area (BSA) Calculation and Height..................................................32
6.6.
ECOG Performance Score ......................................................................................32
&(/*(1(35235,(7$5<,1)250$7,21
9
.........
.......20
20
..............
.............
..............
..........
.............
.............
..............
......
..............
.......
...........
.......
..
..............
...........
.......
...... .......
.....
.............
..........
.............
.............
..............
............
...........
...... ..
..............
.........
onale
nale ......
.....
n ............
.....
alal ...........
..
E OF EVE
E OF EVE
ROCEDUR
OCEDU
Medical 
Medical 
Pririor
3.3.
C
4

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
12
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
6.7.
Peripheral Neuropathy Assessment.........................................................................32
6.8.
Adverse Event Reporting........................................................................................32
6.9.
Lung Cancer Symptom Scale Questionnaire and EQ-5D.........................................32
6.10.
Healthcare Resource Utilization Questionnaire .......................................................32
6.11.
Electrocardiogram ..................................................................................................33
6.12.
CT Scan of the Head or Brain Magnetic Resonance Imaging (MRI) .......................33
6.13.
Bone Scans and X-rays...........................................................................................33
6.14.
Physical Examinations............................................................................................33
6.15.
Vital Signs..............................................................................................................33
6.16.
Laboratory Assessments .........................................................................................33
6.17.
Tumor Tissue Sample Collection and Peripheral Blood Collection 
(Exploratory Assessments) .....................................................................................34
6.18.
Survival..................................................................................................................34
7.
STUDY POPULATION.........................................................................................36
7.1.
Number of Subjects and Sites .................................................................................36
7.2.
Inclusion Criteria....................................................................................................36
7.3.
Exclusion Criteria...................................................................................................37
8.
DESCRIPTION OF STUDY TREATMENTS........................................................39
8.1.
Description of Study Drug(s)..................................................................................39
8.1.1.
nab-Paclitaxel.........................................................................................................39
8.1.2.
Carboplatin.............................................................................................................39
8.2.
Treatment Administration and Schedule .................................................................39
8.3.
Dose Modifications.................................................................................................40
8.4.
Method of Treatment Assignment...........................................................................42
8.5.
Packaging and Labeling..........................................................................................42
8.6.
Study Drug Accountability and Disposal ................................................................42
8.7.
Study Drug Compliance..........................................................................................42
8.8.
Overdose ................................................................................................................42
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................43
9.1.
Permitted Concomitant Medications and Procedures...............................................43
9.2.
Prohibited Concomitant Medications and Procedures..............................................43
9.3.
Required Concomitant Medications and Procedures................................................43
10.
STATISTICAL ANALYSES..................................................................................44
&(/*(1(35235,(7$5<,1)250$7,21
3
.......33
3
..........
.... 33
3
...............
...............
..............
............
on n 
..............
.......
.............
.......
.............
..
....
... ..........
..
.............
..........
..............
.............
TMENTS
TMENT
.............
.............
............
........ ..
..............
.........
tration and
tration and
ions
ns.......
..
Treatment 
Treatment
ging and La
ging and La
udy
dy Drug A
Drug 
y
Study
Study Dru
Dr
y
Over
Over
C
9.1.
9.1

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
13
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
10.1.
Overview................................................................................................................44
10.2.
Study Population Definitions ..................................................................................44
10.2.1.
Intent-to-treat Population........................................................................................44
10.2.2.
Per-protocol (PP) Population ..................................................................................44
10.2.3.
Treated Population..................................................................................................44
10.3.
Sample Size and Power Considerations...................................................................44
10.4.
Background and Demographic Characteristics........................................................46
10.5.
Subject Disposition.................................................................................................46
10.6.
Safety Analysis.......................................................................................................46
10.6.1.
Primary Safety Endpoint.........................................................................................46
10.6.2.
Adverse Events.......................................................................................................47
10.6.3.
Laboratory Assessments .........................................................................................47
10.6.4.
Study Drug Exposure..............................................................................................48
10.7.
Efficacy Analysis....................................................................................................48
10.7.1.
Key Efficacy Endpoints..........................................................................................48
10.7.1.1.
Progression-free Survival........................................................................................48
10.7.1.2.
Overall Survival .....................................................................................................49
10.7.1.3.
Overall Response Rate............................................................................................49
10.7.2.
Exploratory Endpoints............................................................................................49
10.7.2.1.
Health Care Utilization and Quality of Life Questionnaire......................................49
10.8.
Study Therapy Termination ....................................................................................49
10.9.
Deaths ....................................................................................................................49
10.10.
Interim Analysis .....................................................................................................50
10.11.
Scientific Steering Committee ................................................................................50
11.
ADVERSE EVENTS..............................................................................................51
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................51
11.2.
Evaluation of Adverse Events.................................................................................51
11.2.1.
Seriousness.............................................................................................................51
11.2.2.
Severity / Intensity..................................................................................................53
11.2.3.
Causality ................................................................................................................53
11.2.4.
Duration .................................................................................................................54
11.2.5.
Action Taken..........................................................................................................54
&(/*(1(352
rminat
minatioion
..............
...
nalysis
nalysis ....
tific Steerin
ific Steeri
DVERSE 
DVERSE 
Moni
Monitor
tor
i
235,(7$5<,1)250$7,21
4
.......46
4
.........
.... .46
.4
..............
...........
..............
............
.............
.............
..............
............
.............
.............
............
.....
.
..............
...........
.....
.. ........
.......
.............
............
..............
..........
.............
..........
d Qualit
d Quali y 
Eva
Ev
1.2.1.
1.2.1.
11.2.2.
1.2.2.
523

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
14
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
11.2.6.
Outcome.................................................................................................................54
11.3.
Abnormal Laboratory Values..................................................................................54
11.4.
Pregnancy...............................................................................................................54
11.4.1.
Female Subjects......................................................................................................55
11.4.2.
Male Subjects.........................................................................................................55
11.5.
Reporting of Serious Adverse Events......................................................................55
11.5.1.
Safety Queries ........................................................................................................56
11.6.
Expedited Reporting of Adverse Events..................................................................56
12.
DISCONTINUATIONS .........................................................................................57
12.1.
Study Treatment Discontinuation............................................................................57
12.2.
Study Discontinuation ............................................................................................57
12.3.
Subject Replacement ..............................................................................................58
13.
EMERGENCY PROCEDURES.............................................................................59
13.1.
Emergency Contact.................................................................................................59
14.
REGULATORY CONSIDERATIONS...................................................................60
14.1.
Good Clinical Practice............................................................................................60
14.2.
Investigator Responsibilities...................................................................................60
14.3.
Subject Information and Informed Consent.............................................................60
14.4.
Confidentiality........................................................................................................61
14.5.
Protocol Amendments.............................................................................................61
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................61
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................62
14.8.
Closure of the Study ...............................................................................................62
15.
DATA HANDLING AND RECORDKEEPING.....................................................63
15.1.
Data/Documents .....................................................................................................63
15.2.
Data Management...................................................................................................63
15.3.
Record Retention....................................................................................................63
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................65
16.1.
Study Monitoring and Source Data Verification......................................................65
16.2.
Audits and Inspections............................................................................................65
17.
PUBLICATIONS ...................................................................................................66
18.
REFERENCES.......................................................................................................67
5
.......56
5
..........
.... 56
5
..............
...........
..............
............
.............
.............
..............
............
.............
.............
.............
.....
..............
...........
.............
............
.............
............
Consent
Consent.
........
............
.............
....
Board/Indep
Board/Indep
.............
...........
matatioion fo
for I
r
the Study
the Study
HANDLIN
HANDLIN
ta/Docume
ta/Docum
Data Man
Data Man
Reco
Reco
&
.
Q
16.1.
6
2

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
15
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
19.
APPENDICES........................................................................................................69
Appendix A:
ECOG Performance Status Score.......................................................................69
&(/*(1(35235,(7$5<,1)250$7,21

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
16
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
LIST OF TABLES
Table 1:
Blinded Radiology Assessment of Overall Response Rate (ITT Population) ...........20
Table 3:
Table of Events.......................................................................................................28
Table 4:
Permanent Dose Reductions for Hematologic and Neurologic Toxicities and 
Dosing on the Study ...............................................................................................41
&(/*(1(35235,(7$5<,1)250$7,21
.41
41

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
17
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
LIST OF FIGURES
Figure 1:
Overall Study Design..............................................................................................26
&(/*(1(35235,(7$5<,1)250$7,21

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
18
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
1.
INTRODUCTION
1.1.
Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths among men and women worldwide, 
with 1.2 million new cases diagnosed each year. Non-small cell lung cancer (NSCLC) is the 
most common type of lung cancer, accounting for 80% of all new cases. There are an estimated 
1.1 million lives lost per year (approximately 500,000 in the United States [US] and European 
Union [EU] alone) due to NSCLC. Smoking is the causative factor for up to 85% of cases 
(http://www.lungcancercoalition.org/en/pages/about/awareness).
The majority of patients are not diagnosed until the tumor has progressed beyond the primary 
site. Despite step-wise advances in patient selection, targeted agents and optimizing
chemotherapy regimens, patients with advanced NSCLC continue to have an unmet medical 
need (Schiller, 2013).
Platinum-containing chemotherapy regimens remain the standard first-line treatment in the 
majority of patients, in the US and Japan. In the EU, a third-generation chemotherapeutic agent 
(docetaxel, gemcitabine, paclitaxel, or vinorelbine), most commonly gemcitabine or vinorelbine, 
plus a platinum drug is used for advanced NSCLC (NICE, 2011). For first-line therapy in 
patients with Stage IV NSCLC and good performance status, the American Society of Clinical 
Oncology (ASCO) clinical practice guideline recommends treatment with a platinum-based 
two-drug combination of cytotoxic drugs (Azzoli, 2009). A trend that is becoming more 
prevalent is personalized NSCLC treatment based on tumor histology (squamous versus
non-squamous), on molecular characteristics of the tumor, and on the patient’s clinical status 
using agents targeting specific receptors and kinases and pathways (ie, epidermal growth factor 
receptor [EGFR], echinoderm microtubule-associated protein-like 4 [EML4] and anaplastic 
lymphoma kinase [ALK] fusion protein).
In advanced NSCLC, the prevalently used combination of solvent-based paclitaxel/carboplatin 
results in modest response rate, survival, and toxicity. Paclitaxel is currently available in the 
proprietary product Taxol®(paclitaxel) Injection, manufactured by Bristol-Myers Squibb (New 
York, NY) and by several other generic drug manufacturers. Taxol consists of paclitaxel 
dissolved in a proprietary solvent, Cremophor® EL (BASF, Ludwigshafen, Germany), and 
ethanol. While this solvent system addresses the poor water solubility of paclitaxel, the Taxol 
formulation has a number of other limitations. For example, Taxol administration requires 
routine premedication with corticosteroids, diphenhydramine, and H2 antagonists to reduce the 
incidence of hypersensitivity reactions and histamine release caused by a response to the 
formulation vehicle (Gelderblom, 2001; Lorenz, 1997; Weiss, 1990). Furthermore, the solvent 
alters drug pharmacokinetics (PK), leading to highly increased systemic drug exposure, 
decreased drug clearance, nonlinear PK, and lack of dose-dependent antitumor activity 
(Sparreboom, 1999; ten Tije, 2003; van Tellingen, 1999). Also, Taxol must be administered over 
a period of either 3 hours or 24 hours, and requires the use of specialized infusion sets and in-line 
filters that do not contain di[2-ethylhexyl] phthalate (DEHP).
Compared with solvent-based paclitaxel, nab-paclitaxel exhibits 10-fold higher mean Cmax of 
free paclitaxel, delivers 33% higher drug concentration to tumors in preclinical xenograft 
&(
(
&(/*(1(35235,(7$5<,1)250$7,21
he primary
he primary
ing
ing
unmet med
nmet med
line treatm
line treatm
ion n chem
chemo
nly gemci
gemc
y
ti
11
11). For fir
). For f
us, the Ame
, the Am
nds treatme
nds treatm
09
09).). A tren
A tren
on tumor h
on tumor h
f the tumor,
the tumo
kinases an
kinases an
e-associ
associate
ate
n).
n).
ly used co
ly used co
survival, a
survival, a
pacli
paclitaxel) 
taxel) 
i
other gene
other g
ary
ary solvent
solvent
y
solvent sy
lvent sys
number o
number o
dicat
icatioion wi
n w
f f hypersen
hypersen
ion vehicle
vehicl
s drug 
drug pharm
pha
creased dru
creased dru
Sparreboo
Sparrebo
period
perio

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
19
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
models, and demonstrates enhanced transport across endothelial cell monolayers (Desai, 2006; 
Gardner, 2008). The Cremophor EL-free medium enables nab-paclitaxelto be given in a shorter
duration without the need for premedication to prevent solvent-related hypersensitivity reactions.
In addition, standard tubing and intravenous (IV) bags may be used for the IV administration of 
nab-paclitaxel. nab-Paclitaxel for Injectable Suspension is approved for the treatment of 
metastatic breast cancer (globally) and for the treatment of adenocarcinoma of the pancreas (US). 
For NSCLC, nab-paclitaxel is approved in the US in combination with carboplatin for first-line 
treatment of patients with locally advanced or metastatic NSCLC who are not candidates for 
curative surgery or radiation therapy. The recommended dose of nab-paclitaxel for the NSCLC 
indication is 100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1, 8, 
and 15 of each 21-day cycle.
1.2.
nab-Paclitaxel in NSCLC
The Food and Drug Administration (FDA) approval of nab-paclitaxel was based on the 
evaluation of Phase I and II data (Belani, 2008; Rizvi, 2008; Socinski, 2010), as well as the 
pivotal Phase III study (CA031). The pivotal Phase III study was a multicenter, randomized, 
open-label study conducted in 1052 chemo naive subjects with Stage IIIB/IV non-small cell lung 
cancer to compare nab-paclitaxel in combination with carboplatin to paclitaxel injection in 
combination with carboplatin as first-line treatment in patients with advanced non-small cell lung
cancer. nab-Paclitaxel was administered as an intravenous infusion over 30 minutes at a dose of 
100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as 
an intravenous infusion over 3 hours at a dose of 200 mg/m2, following premedication. In both 
treatment arms carboplatin at a dose of AUC = 6 mg*min/mL was administered intravenously on 
Day 1 of each 21-day cycle after completion of nab-paclitaxel/paclitaxel infusion. Treatment was
administered until disease progression, development of an unacceptable toxicity or patient 
withdrawal. The primary efficacy outcome measure was ORR as determined by a central 
independent review committee using RECIST guidelines (Version 1.0). In the intent-to-treat (all-
randomized) population, the median age was 60 years, 75% were men, 81% were white, 49% 
had carcinoma/adenocarcinoma, 43% had squamous cell lung cancer, 76% were ECOG PS 1, 
15% were ≥70 years of age and 73% were current or former smokers. Patients received a median 
of 6 cycles of treatment in both study arms. Patients in the nab-paclitaxel/carboplatin arm had a 
statistically significantly higher overall response rate compared to patients in the paclitaxel 
injection/carboplatin arm [(33% versus 25%), see Table 1].
Non-inferiority analysis of overall survival (OS) demonstrated that nab-paclitaxel/carboplatin
(nab-p/C) treatment is not inferior to solvent-based paclitaxel/carboplatin (sb-P/C) treatment. 
Overall survival in the nab-paclitaxel arm was 12.1 months versus 11.2 months in the control 
arm (p = 0.271; HR = 0.922).  Toxicities, particularly neuropathy and neutropenia were less 
pronounced using nab-paclitaxel in the dose and schedule employed.
&(/*(1(35235,(7$5<,1)250$7,21
LC
1, 8, 
1, 8, 
sed on the
sed on the
0), as well 
), as well 
icenter,
center, ran
IIIB
IIIB/IV no
/IV n
n to paclitax
o paclitax
wi
with
th
i
advan
a
h
nfusio
nfusion ove
n ove
clitaxel
clitaxel inj
mg/m
g/m
m
2, f
, fol
ol
f l
mg*min/mL
min/mL
nab
ab-paclita
paclita
opment of a
opment of 
measure 
measure 
ECIST g
ECIST guiu
age was 60
age was 
43% had sq
43% had s
d 73% were
73% wer
both study
oth study
higher
higher ove
o
rm
rm [(33% 
[(33%
m
nalysis of 
nalysis of o
ment i
ent is not
s n
ival
ival in the
in the
0.271; HR
271; HR
unced using
unced usin

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
20
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Table 1:
Blinded Radiology Assessment of Overall Response Rate (ITT Population)
Variable
Category/Statistic
nab-Paclitaxel/
Carboplatin
(N=521)
sb-Paclitaxel/
Carboplatin
(N=531)
Response Rate 
Ratio
(pA/pT)a
p-value
Patients with Confirmed Complete or Partial Overall Response
n (%)
170 (33%)
132 (25%)
1.313
0.005*
Confidence Interval (CI) b
28.6, 36.7
21.2, 28.5
1.082, 1.593
Complete Response, n (%)
0
1 (< 1%)
Partial Response, n (%)
170 (33%)
131 (25%)
a PA/PT equals response rate of nab-paclitaxel/response rate of sb paclitaxel.
b 95% CI of response rate and 95.1% CI of response rate ratio.
* Indicates p-value < 0.049.Note: P-value is based on a chi-square test.
Source: Data on File.
Adverse events were assessed in 514 nab-paclitaxel/carboplatin-treated patients and 524 
paclitaxel injection/carboplatin-treated patients. The following common (≥ 10% incidence) 
adverse events were observed at a similar incidence in nab-paclitaxel and paclitaxel arms: 
alopecia 56%, nausea 27%, fatigue 25%, decreased appetite 17%, asthenia 16%, constipation 
16%, diarrhea 15%, vomiting 12%, dyspnea 12%, and rash 10% (incidence rates are for the nab-
paclitaxel plus carboplatin treatment group).
1.3.
Rationale for Further Study of nab-Paclitaxel as First-line Treatment 
in Elderly Subjects with Advanced NSCLC
The tolerability of doublet chemotherapy in elderly patients with advanced NSCLC is an
important therapeutic consideration, whereby the landmark IFCT 0501 reported that first-line sb-
paclitaxel given weekly three weeks out of four coupled with carboplatin every 4 weeks (i.e.
21days of treatment followed by one-week break) improved efficacy over single-agent 
chemotherapy (either gemcitabine or vinorelbine) in patients 70 years or older with advanced 
NSCLC. The results demonstrated that doublet chemotherapy was feasible in this elderly
population with an acceptable toxicity profile, when sb-paclitaxel/carboplatin was given as 21
days of treatment followed by one-week rest. The combination also resulted in a significant 
improvement in OS (median, 10.3 versus 6.2 months; HR = 0.639, 95% CI:0.52-0.79, p <
0.0001), with 1-year survival rates of 45.1% versus 26.9% for doublet therapy and monotherapy.  
This prospective trial set a standard, against which doublet-regimens must be measured in the 
elderly population with advanced NSCLC.
In the CA031 study of nab-paclitaxel (Abraxane) in combination with carboplatin, patients were 
stratified by age (< 70 years old versus ≥ 70 years old). Fifteen percent of ITT patients were 
elderly (≥70 years: nab-paclitaxel, n = 74: sb-paclitaxel, n = 82). Baseline characteristics were 
generally well balanced between treatment arms in elderly population, and subgroup analyses 
were performed to assess the influence of age on the primary efficacy endpoint of overall 
response rate as well as PFS and OS (Socinski, 2013). 
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
50
50
50
250
5
treated pati
ated pati
g comm
g common
o (
n
paclitaxel
paclitaxe
etite 17%, a
ite 17%
d rash 10%
d rash 10%
dy y of 
of nab
nab
Advance
dvance
apy
py
a
i
y n elde
n e
n, whereby
, whereby
weeks out o
eeks out o
d by
d by one-
one w
mcitabine o
mcitabin
emonstrate
emonstrate
acceptable 
ceptable 
t fol
ol
f lolowed 
wed
in OS (med
n OS (me
ith 1
th 1-ye
year s
ar s
ospective tr
ospective tr
lyly popul
popul
y
atati
n th
the CA03
CA03
stratified
tratified
derl
d l

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
21
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Of note, the post-hoc analysis of the CA031 trial showed marked improvement in survival in the 
nab-paclitaxel/carboplatin arm. Amongst 156 elderly (≥70 years of age) subjects randomized on 
the study, OS was 19.9 months versus 10.4 months (HR: 0.583, p = 0.009) in favor of the nab-
p/C arm compared to sb-p/C. The proportion of patients who had complete or partial response 
were consistently higher in all age stratum groups for the nab-paclitaxel/carboplatin regimen 
relative to the sb-paclitaxel/carboplatin regimen (in patients ≥ 70 years of age 34% versus 24% 
respectively, ratio of rates 1.385, p = 0.196, 
).
 
 
 
Although it was a statistically significant treatment effect in favor of nab-paclitaxel in the elderly 
subgroup from CA031 trial, 46% of patients in the nab-paclitaxel/carboplatin arm experienced 
dose reductions or dose delays. Approximately 92% of dose modifications and reductions were 
due to AEs. The most common clinical AEs in this subgroup were hematologic Grade ≥ 3 
neutropenia (45%), anemia (22%) and thrombocytopenia (19%). Approximately 18% of the 
elderly population in the CA031 trial had Grade ≥ 2 peripheral neuropathy. Despite that,
approximately 10% more elderly patients in the nab-paclitaxel arm were able to receive second-
line therapy compared to sb-paclitaxel (61% versus 50%, respectively), possibly because they 
may have been in better shape due to a better tolerated first-line regimen with nab-paclitaxel or 
better disease and symptom control as demonstrated as improvement in ORR.
The results from the elderly subset in CA031 trial showed the combination of nab-paclitaxel and 
carboplatin to be particularly promising. We hypothesize that the tolerability can be improved 
further by introducing a one week break at the end of each treatment cycle (similar to the 
schedule advocated by Quoix, 2011) among elderly patients.  Reducing the rate of the most 
common AEs (Grade ≥ 3 myelosuppression toxicities and Grade ≥ 2 peripheral neuropathy) by 
16% will be clinically meaningful as it can potentially improve tolerability, quality of life and 
allow patients to receive treatment for a longer period of time, without necessarily compromising 
efficacy.  
&(/*(1(35235,(7$5<,1)250$7,21
0$
2
$
)2
)2
)2
)2
1)
,1
<
5<
ment effect i
ent effect
in the
n the nab
nab
ately 92% 
ately 92% 
AEs in thi
AEs in th
nd thrombo
d thromb
rial had Gr
rial had G
rly pat
rly patieientn
paclitaxel
paclitaxe
shape due t
shape du
mptom con
mptom co t
the elderly 
he elderly 
be particula
be particu
troducing
roducing
advocated 
vocated 
on AEs (
AEs (G
% will be cl
% will be c
allow pat
llow patieie
efficacy
fficac
25
1
,1
< ,1
<

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
22
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
2.
STUDY OBJECTIVES
2.1.
Primary Objectives 
!
To assess the safety and tolerability of continuous weekly versus weekly times three 
with one-week break nab-paclitaxel (Abraxane) in combination with carboplatin as 
first-line treatment for advanced NSCLC in elderly subjects (≥ 70 years old).
2.2.
Secondary Objective
!
To evaluate the efficacy of nab-paclitaxel in combination with carboplatin in elderly 
subjects with advanced NSCLC.
2.3.
Exploratory Objectives
!
To assess healthcare resource utilization for the two nab-paclitaxel treatment arms.
!
To assess the Lung Cancer Symptom Scale (LCSS) and EuroQol Group 5-Dimension 
Self-Report Questionnaire score (EQ-5D) for the two nab-paclitaxel treatment arms.
!
 
 
!
 
&(/*(1(35235,(7$5<,1)250$7,21
in elderly
n elderly
taxel treatm
axel tr
EuroQol
uroQol Gr
Gr
l
nab
ab-pacli
aclitax
ta
i
5<
7$5
(7$

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
23
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint
!
The primary study endpoint is the percentage of subjects with either peripheral 
neuropathy of Grade ≥2 or myelosuppression AEs of Grade ≥3 based on the local
laboratory values for ANC, platelet count, and hemoglobin. All AEs will be graded 
using NCI CTCAE v4.0. 
3.2.
Secondary Endpoints
The secondary endpoints are: 
3.2.1.
Safety
!
The type, frequency, and severity of AEs and SAEs. 
!
Discontinuation rate.
!
Dose intensity administered.
!
The incidence of dose reduction and dose delay.
3.2.2.
Efficacy
!
Progression-free Survival (PFS).
!
Overall response rate (ORR) using RECIST v1.1 guidelines.
!
Overall Survival (OS).
3.3.
Exploratory Endpoints
!
Healthcare resource utilization during the study using a questionnaire.
!
Changes in the LCSS and EQ-5D.
!
 
!
 
 
!
Additional exploratory endpoints may be defined in the statistical analysis plan 
(SAP), if applicable.
&(/*(
!
Addi
Addi
(S
(1(35235,(7$5<,1)250$7,21
g RECIST 
RECIST 
nts
nts
ututilization 
ilization
LCSS
LCSS and 
an E
( 3
1(
(1(
*(1
/*(

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
24
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
4.
OVERALL STUDY DESIGN
4.1.
Study Design
This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus
weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-
line treatment in elderly subjects (≥ 70 years old) with advanced NSCLC who are not candidates 
for curative surgery or radiation therapy.
Subjects will be randomized 1:1 to receive one of the following treatments:
Arm A (21-day treatment cycle):
!
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, 
and 15 of each 21-day treatment cycle
!
Carboplatin AUC = 6 mg*min/mL IV on Day 1 of each 21-day treatment cycle after 
completion of nab-paclitaxel infusion 
Arm B (21-day treatment followed by one-week break cycle, 28-day duration):
!
nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, 
and 15 of each 21-day treatment  followed by one-week break cycle
!
Carboplatin AUC = 6 mg*min/mL IV on Day 1 of each 21-day treatment followed by 
one-week break cycle, after completion of nab-paclitaxel infusion 
The study will consist of a 28-day Screening Period, a Treatment Period, and a Follow-up
Period.
The Screening Period will start from signing the Informed Consent Form (ICF) until first dose of 
study drug. 
The Treatment Period will start from first dose of study drug until End-of-Treatment Visit 
(which is defined as visit with last dose of study drug).
Follow-up Period will start after End-of-Treatment visit.
No additional anticancer agents are allowed during study treatment. All supportive care
(including but not limited to growth factors, antiemetics, analgesics, zolendronic acid, 
denosumab) is permitted as per the investigator’s discretion and should be administered 
according to local institutional practice. Subjects will continue treatment until disease 
progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of 
consent, in accordance with local standard of care.
Tumor evaluations will be assessed locally and response (Complete Response [CR] or Partial 
Response [PR]) will be determined according to RECIST guidelines, Version 1.1. In both 
treatment arms, tumor assessments will be conducted at screening, every 42 days (-3/+7 days) 
(starting from Day 1 Cycle 1) until disease progression (even if treatment has been 
discontinued), withdrawal of consent, lost to follow-up, death or if clinically indicated while on 
treatment.
&(/
m
(/*(1(35235,(7$5<,1)250$7,21
on Day
on Days 1,
s 1
y treatm
treatment
ay duration
ay duratio
< ,
n over 30 m
n over 3
e-e-week
week bre
br
ay
ay 1 of
1 of
y
eac
eac
f
f f nab
nab-pacl
pa
ririod
od, a a Trea
Tr
ning 
ning th
the Inf
om
om f
m irst do
irst d
f
last dose of
ast dose of
after 
after End
End
erer agents
age
a
imited to gr
mited to gr
ermitted as
ermitted as
ocal
cal inst
instititu
n, developm
, developm
 in accorda
in accord
or evaluat
or evaluat
Response 
Response [P
[P
treatm
reatmen
e
artiti

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
25
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Local laboratory test data for ANC, platelet count, hemoglobin and serum creatinine will be 
collected in the eCRFs. All other routine laboratory test data except those mentioned above will 
not be collected in the eCRF unless they are determined to be clinically significant laboratory 
abnormalities. A clinically significant laboratory abnormality will be reported as an AE, or SAE, 
and the specific associated laboratory parameter(s) should be recorded in the laboratory 
assessments eCRF. Local safety laboratory data will also be the primary guide for eligibility and 
subject management. In addition, test results for tumor mutational status of genes including but 
not limited to EGFR, ALK, and KRAS will be collected and recorded on eCRF if these tests 
have been performed locally for routine diagnosis.  
4.1.1.
Follow-up Period
All subjects who discontinue from treatment for reasons other than withdrawal of consent or lost 
to follow-up, will enter the Follow-up Period. It will consist of a visit 28 days after treatment 
discontinuation following by follow-up for survival approximately every 90 days (+/- 14 days or 
when they are seen for routine care) by phone call or chart review for documentation of last 
contact for up to 6 months after the last subject is randomized or 192 PFS events have been 
observed, whichever comes later.
Those subjects entering the Follow-up Period without documented progression will continue to 
have CT scans in accordance with standard of care (at least every 90 days) until documented 
progression of disease, withdrawal of consent, lost to follow-up, death or study closure.
4.2.
Study Design Rationale
The nab-paclitaxel schedule used in Arm A is in accordance with pivotal trial CA031,
ie,100 mg/m2 administered once per week on Days 1, 8 and 15 combined with carboplatin 
AUC = 6 mg*min/mL administered on Day 1 every 21 days, as approved by the FDA.  The nab-
paclitaxel/carboplatin schedule used in Arm B is the same schedule as the current approved nab-
paclitaxel label with introduction of a one-week break following 21 days of treatment. This 
study will determine whether the one-week break can further improve tolerability without 
compromising efficacy (similar to the schedule advocated by Quoix, 2011) among elderly 
patients.  Reducing the rate of the most common AEs (Grade ≥ 3 myelosuppression toxicities 
and Grade ≥ 2 peripheral neuropathy) by 16% will be clinically meaningful as it can potentially 
improve tolerability, quality of life and allow subjects to receive treatment for a longer period of 
time.
onsent
nsent or 
or lol
er treatm
er treatmen
e
ays 
ays (+/
+/- 14
- 14
mentation 
mentation 
S events ha
event
ed progress
progres
very
ery 90 day
90 d
y
w-up, 
up, death
dea
accordance
accordanc
Day
Days 1, 8 a
s 1, 8 a
y 1 every
1 every
y
2
Ar
Arm B isis th
one-
one-week
we
ne-week
week b
to the sche
to the sche
of the most 
of the most
neuropathy
neuropathy
ualit
uality of lif
y of lif

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
26
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Figure 1:
Overall Study Design
&(/*(1(35
1( 35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5<
5
7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(7
(
3
( 3
( 3
( 3
( 3
( 3
(
(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1(
1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(1
(

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
27
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
4.3.
Study Duration
Recruitment is expected to take approximately 24 months, and the analysis of PFS will be 
performed when approximately 192 PFS events have occurred, estimated as approximately 28
months from first subject randomized. The total length of this Phase IV study with follow-up is 
estimated to last approximately 3 years.
4.4.
End of Trial
The End of Trial is defined as either the:
!
date of the last visit of the last subject to complete the study, or 
!
the date of receipt of the last data point from the last subject that is required for primary, 
secondary and/or exploratory analysis, as pre-specified in the protocol and/or the SAP, 
whichever is the later date.
&(/*(1(35235,(7$5<,1)250$7,21
for 
or
f
primar
prima
nd/or the SA
d/or the S

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
28
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
5.
TABLE OF EVENTS
Table 3:
Table of Events
Screening
/ Baseline
Treatment Perioda
Every cycle starting with Cycle 1
Follow-Up Period
Assessment
Day -28 
to
Day -1
Day 1
( ±2 days)
Day 8
(±2 
days)
Day 15
(±2 
days)
Every 42 days 
(-3/+7 days) 
(counting from 
Day 1 Cycle 1)
End-of-
Treatment
Visit (last dose 
of study drug)
28-day Follow-up 
Visit (after last 
dose of study 
drug)
Survival Follow-Upb
Every 90 days (+/-
14 days) (after 28-
day follow-up visit)
Informed Consent
X
-
-
-
-
-
-
-
Medical History, Prior Medication and Procedures
X
-
-
-
-
-
-
-
CT Scan of Complete Chest (including base of neck 
and adrenal glands) and any other studies required 
for Tumor Imagingc
X
-
-
-
X c
X c
-
X c
Weight and Heightd
X
X
X
X
-
-
-
-
Body Surface Area (BSA) Calculationd
X
-
-
-
-
-
-
-
ECOG status
X
X
-
-
-
X
X
-
Concomitant Medication/Procedures
-
X
X
X
-
X
X
X
Peripheral Neuropathy Assessmente
X
X
X
X
-
X
X
-
Healthcare Resource Utilization Questionnaire
-
X
-
-
-
X
X
-
Hematologyf (ANC, platelet count, Hgb)
X
X
X
X
-
X
X
-
Serum Chemistryf (serum creatinine)
X
X
-
-
-
X
X
-
&(/*
pri
prietet
/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
0$
25
-
ment
ment
(last dose 
(last dose 
f study drug)
study d
28-
28-day
d
Vi
25
25
25
-
1)
,1
< ,
X c
<
7$ <
X
7$
7$
(7$
-
(7
(7
(7
5,(7
-
-
-
-
5,
5,
5,(
5,
X
35
235
X
X
X
23
23
23
23
X
52
X
35
3
X
3
(
/*
/*(1(

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
29
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Table 3:
Table of Events (Continued)
Screening
/ Baseline
Treatment Perioda
Every cycle starting with Cycle 1
Follow-Up Period
Assessment
Day -28 
to
Day -1
Day 1
( ±2 days)
Day 8
(±2 
days)
Day 15
(±2 
days)
Every 42 days 
(-3/+7 days) 
(starting Day 1 
Cycle 1)
End-of-
Treatment
(last dose of 
study drug)
28-day Follow-up 
Visit (after last 
dose of study 
drug)
Survival Follow-Upb
Every 90 days (+/-
14 days) (after 28-
day follow-up visit)
Blood for Pharmacogenomic Analyses
-
X
(C1D1 only)
-
-
-
-
-
-
Adverse Event Evaluation
After signing ICF and until 28 days after the last dose of study drug
nab-paclitaxel Administration/accountabilityg
-
X
X
X
-
-
-
-
Carboplatin Administration/accountabilityg
-
X
-
-
-
-
-
-
LCSS and EQ-5D
-
X
-
-
-
X
X
-
Survival phone call (or chart review for 
documentation of last contact or when they are seen 
for routine care
-
-
-
-
-
-
-
Xb
Electrocardiogram (ECG)
Will be done as per standard of care at screening, during the Treatment Period and as clinically indicated; however, results 
will not be routinely collected in the eCRFs. Results will be collected in the eCRFs as AE or SAE only if results are abnormal 
and clinically significant.
CT Scan of the Head or Brain Magnetic Resonance 
Imaging (MRI)
Bone Scan (X-rays if needed)
Physical Examination
Vital Signs
AE = Adverse Event; ANC = absolute neutrophil count; C1D1 = Cycle 1, Day 1; CT = Computed Tomography; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic 
Case Report Form; EQ-5D = EuroQol 5D; ICF = informed consent form; LCSS = Lung Cancer Symptom Scale; SAE = Serious Adverse Event.
a Treatment Period:  Arm A: nab-paclitaxel Days 1, 8, and 15 and carboplatin Day 1. Arm B: nab-paclitaxel Days 1, 8, and 15 and carboplatin Day 1 followed by one-week break.
b Every 90 (+/-14) days (from 28-day Follow-up Visit) or when they are seen for routine care for up to 6 months after the last subject is randomized or 192 PFS events have been 
observed, whichever comes later.
c All subjects must have a radiographically documented measurable tumor(s) by RECIST Version 1.1 criteria: CT scan of complete chest (including base of neck and adrenal 
glands) are performed at screening, every 42 days (-3/+7 days) thereafter (counting from Day 1 Cycle 1) until disease progression, withdrawal of consent, lost to follow-up, 
death and if clinically indicated while on treatment. The methods of assessment chosen at baseline to follow tumors are to remain consistent throughout study duration. Those 
subjects entering the Follow-up Period without documented progression will continue to have CT scans in accordance with standard of care (at least every 90 days) until 
documented progression of disease, withdrawal of consent, lost to follow-up, death or study closure.
d BSA will be calculated at screening and recalculated if body weight changes by more than 10% during the study. Height will only be obtained at Screening Visit. Weight will be 
obtained at screening and every visit during the Treatment Period before administration of study drug, but will only be collected on the eCRF for the Screening Visit.
&(
pri
prietet
(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
Follow
Follow-Up
Up
7,2
)
day Follow
ollow-u
Visit (after la
Visit (after l
dose of st
dose of st
dru
dr
0$
25
25
25
25
dose
dose of study
of stu
)2
-
1
< ,
< ,
< ,
< ,1
< ,
-
5<
-
$5
(7
ard of care at 
d of care at 
ected in the e
ected in the
(7
(7
(7
35
= Cycle 1, Da
= Cycle 1
consent form
onsent form
and 15 and ca
and 15 and ca
sit) or when th
t) or when t
cumented me
cumented me
y 42 days
42 days (-( 3/+
3/
on treatment.
on treatment.
riod without d
d without d
ase, withdraw
se, withdraw
ening
ening and rec
and re
very visit dur
ery visit dur

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
30
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
e The occurrence of peripheral neuropathy will be reported by the investigator per protocol as an AE or SAE.
f Laboratory assessments will be done prior to each nab-paclitaxel treatment as per standard of care during the study and as clinically indicated. ANC, platelet count, hemoglobin
(Hgb) level and serum creatinine results will be collected in the eCRFs (all other routine laboratory test data except those mentioned above will not be collected in the eCRF
unless it is clinically significant, which will then be reported as AEs or SAEs, and the specific associated laboratory parameter(s) should be recorded on the laboratory 
assessments eCRF).
g nab-Paclitaxel administration followed by carboplatin administration.
&(/*(1(35235,(7$5<,1)250$7
pri
prietet
$7,21
e Corpora
e Corpora
21
atelet count,
atelet count, h
be collected in
e collected i
ded on the lab
ed on the la

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
31
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
6.
PROCEDURES
Subjects will be provided with a written ICF, given the opportunity to ask any questions 
concerning the study and will sign an ICF prior to participating in any study procedures. After 
giving written informed consent, subjects will undergo a Screening Period to be assessed for 
eligibility. All subjects who sign an ICF must be entered into the Interactive Randomization 
Technology (IRT) system immediately upon signature on the document. Subjects who do not 
meet the eligibility criteria will be considered screening failures and will not be eligible for the 
study. Subjects who screen fail may re-screen up to 2 times at any time and an ICF will need to 
be re-signed, as well as all screening procedures repeated (some procedures may not need to be 
done if previously done within 28 days prior to screening again). Subjects that have met all 
eligibility criteria after the Screening Period will be eligible to be randomized. 
6.1.
Medical History
Only clinically significant or ongoing medical conditions will be recorded at screening on the 
eCRF. 
6.2.
Prior and Concomitant Medications/Procedures
Prior medications are considered any medications stopped prior to the date of the first dose of 
study drug. Only prior medications/procedures (of clinically significant or ongoing medical 
conditions) within 28 days of time of signature on the ICF should be recorded. All NSCLC-
related prior medications/procedures (including radiation therapy) should be recorded regardless 
of time. 
Concomitant medications and procedures are considered any medications or procedures that 
were taken on or after the date of the first dose of study drug. All subjects will have concomitant 
medications and procedures (including radiation therapy) recorded from the time of signature on 
the ICF until the 28-day Follow-up Visit, for conditions that are clinically significant or ongoing. 
During the Follow-up Period only NSCLC-associated concomitant medications/procedures 
(including radiation therapy) will be recorded, ie, subsequent-line(s) of anti-cancer therapy.
6.3.
Computed Tomography (CT) Scan of Complete Chest (including 
base of neck and adrenal glands)
A CT scan of complete chest (including base of neck and adrenal glands) and any other studies 
required for tumor imaging will be done at screening, every 42 days (-3/+7 days) (starting from 
Day 1 Cycle 1) until treatment discontinuation or withdrawal of consent. Those subjects entering 
the Follow-up Period without documented progression will continue to have CT scans in 
accordance with standard of care (at least every 90 days) until documented progression of 
disease, withdrawal of consent, lost to follow-up, death or study closure. Additional CT scans
may be done at any time during the study if clinically indicated. All CT scans and reports should 
be archived at the site according to site regulations and copies provided to Sponsor if requested.
e
ed to
d to
ed to be
ed to be
met all
met all
ed at 
at screen
cr
edures
dur
pririor to the
or to th
cally signifi
cally signi
e ICF shoul
e ICF sho
diat
diation ther
n the
re co
consider
nside
st dose of s
st dose of
ng radiat
ng radiation
p V
p Visit
i
, for 
f
nly 
ly NSCLC
NSCLC
will be rec
will be 
d Tomog
d Tomog
f neck an
f neck an
omp
mplete
lete ch
tum
tumor ima
or ima
ycle 1
e 1) ) until
until
low
low-up Pe
p Pe
ordance wi
ordance wi
disease
sease, wi
witi
may be d
may be
arc

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
32
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
6.4.
Weight
Weight will be obtained at screening and at every visit during the Treatment Period before 
administration of study drug, but will only be collected on the eCRF for the Screening Visit.
Additional weights may be collected per local standards at any time during the study as needed.
6.5.
Body Surface Area (BSA) Calculation and Height
Height will be collected at screening only, and BSA will be calculated at screening of the study.
BSA will be recalculated if body weight changes by more than 10% during the study.
6.6.
ECOG Performance Score
Eastern Cooperative Oncology Group performance score will be collected at screening, Day 1 of 
every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. 
Additional ECOG assessments may be performed at any time during the study as clinically 
indicated.
6.7.
Peripheral Neuropathy Assessment
Peripheral neuropathy (sensory or motor) assessment will be done at screening, Day 1, 8, 15 of 
every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes 
in neuropathy grade from baseline will be reported as an AE as per Section 11. Additional 
peripheral neuropathy assessments may be done at any time during the study as clinically 
indicated.
6.8.
Adverse Event Reporting
Adverse events will be recorded from time of signature on the ICF until 28 days after the last 
dose of study drug, including any unscheduled visits. See Section 11 for details. 
6.9.
Lung Cancer Symptom Scale Questionnaire and EQ-5D
The LCSS and EQ-5D questionnaires will be used to measure quality of life (QoL) for subjects 
in the study. The LCSS is comprised of 9 questions to be completed by the subject using a visual 
analogue scale (VAS) to denote intensity of a symptom. The EQ-5D comprises 5 questions on 
mobility, self-care, usual activities, pain/discomfort, anxiety/depression and a VAS for overall 
QoL. These questionnaires will be completed at Day 1 of every Treatment Period, at the End-of-
Treatment Visit and at the 28-day Follow-up Visit.
6.10.
Healthcare Resource Utilization Questionnaire
A healthcare resource utilization questionnaire will be used to capture the additional use of 
healthcare resources, including hospitalizations, emergency room visits, doctor or nurse visits, 
procedures, and/or additional medication during the study period. The assessment will be 
completed at Day 1 of every treatment cycle, at the End-of-Treatment visit and at 28-day Follow-
up Visit. 
&(/*(1(35235,(7$5<,1)250$7,21
ning, Day 1
ning, Day 1
p V
p Visit
isit. .
y as 
as
y
clinica
nica
e atat screen
en
e 28-
28 day 
day Fo
AE as per Se
as per S
time during
time durin
 of signatu
of signatu
heduled visi
eduled vi
ptom 
ptom Sca
Sca
onnaires wi
onnaires w
comprised 
omprised
o denote int
o denote i
sual
ual act
ac
l
ivit
iv
onnaires w
nnaires w
and at
and at th
t e
Healthc
Healthc
alt
althcare
hcar res
re
althcare re
hcare re
procedure
procedure
om
omple
ple
m

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
33
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
6.11.
Electrocardiogram
Electrocardiograms (ECGs) will be done per standard of care at screening, during the Treatment 
Period and as clinically indicated. Results will be collected in the eCRFs as AE or SAE only if 
results are abnormal, changed and clinically significant.
6.12.
CT Scan of the Head or Brain Magnetic Resonance Imaging (MRI)
A CT scan of the head, or preferably brain MRI, will be done as per standard of care at 
screening, during the Treatment Period, and as clinically indicated. Results will be collected in 
the eCRFs as an AE or SAE only if the results are abnormal and clinically significant.
6.13.
Bone Scans and X-rays
Bone scans and x-rays will be done as per standard of care at screening, during the Treatment 
Period, and as clinically indicated. Results will be collected in the eCRFs as AE or SAE only if 
results are abnormal and clinically significant.
6.14.
Physical Examinations
Physical examinations will be done as per standard of care at screening, during the Treatment 
Period, and as clinically indicated. Results will be collected in the eCRFs as AE or SAE only if 
results are abnormal and clinically significant.
6.15.
Vital Signs
Vital signs will be done as per standard of care at screening, during the Treatment Period, and as 
clinically indicated. Results will be collected in the eCRFs as AE or SAE only if results are 
abnormal and clinically significant.
6.16.
Laboratory Assessments
Laboratory assessments will be done as indicated in Table 3 by local laboratories as per standard 
of care during the study and as clinically indicated. Local laboratory test data for ANC, platelet 
count and hemoglobin must be collected at screening, each visit before administration of study 
drug, at the End-of-Treatment visit and at the 28-day Follow-up Visit in the eCRF. Serum 
creatinine must be collected at screening, Day 1 of each cycle, at the End-of-Treatment visit and 
at the 28-day Follow-up Visit in the eCRF. Normal ranges for these selected parameters will be 
collected on the eCRF. All other laboratory test data, except those mentioned above, will not be 
collected routinely in the eCRF. Local safety laboratory data will also be the primary guide for 
eligibility and subject management. It is the responsibility of the investigator to assess the 
clinical significance of all abnormal values as defined by the reference ranges from the local 
laboratory. All clinically significant laboratory abnormalities (Section 11.3) are to be recorded as 
AEs on the AE eCRF, and the specific laboratory parameter(s) as well as the corresponding 
normal ranges should be recorded on the laboratory assessments eCRF. Clinically significant 
laboratory abnormalities at screening may result in subject ineligibility for the study and should 
not be captured as AE. Any abnormal values that persist should be followed at the discretion of 
the investigator. The investigator should file all copies of the reports, including faxes with the 
subject’s medical chart.
&(/*(1(35235,(7$5<,1)250$7,21
n 
he
he Treatme
Treatme
AE or SAE
AE or SAE
reening,
eeni
dur
du
n the eCRF
 the eCR
t screening
creening
n the eCR
n the eCR
ents
ents
one
one as ind
as ind
s clinically
s clinically
st be collec
be collec
tm
tment visi
vis ti
ollected at s
llected at
ow-
w-up Visi
up Visi
e eCRF.
eCRF. Al
uti
utinely
nely
i
in th
n t
y and subje
nd subje
al significan
al significan
oratory
ratory. All
. Al
AEs on the 
AEs on the
norm
nor alal r
l
ora

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
34
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
6.17.
Tumor Tissue Sample Collection and Peripheral Blood Collection
(Exploratory Assessments) 
Provision of tumor tissue is mandatory for study enrollment, except when no tumor tissue is 
extant and this requirement would necessitate a new procedure such as a biopsy to collect it.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, test results for tumor mutational status of genes including but not limited to EGFR, 
ALK, and KRAS will be collected and recorded on eCRF if these tests have been performed
locally for routine diagnosis.
 
 
 
 
 
 
6.18.
Survival 
After the End-of-Treatment Visit, the subjects will have a 28-day Follow-up Visit followed by a 
call or chart review for documentation of last contact approximately every 90 days (or when they 
are seen for routine care) for up to 6 months after the last subject is randomized or 192 PFS 
events have been observed, whichever comes later. The subjects will also be asked questions 
about other medications they may be taking for their NSCLC or their medical records will be 
reviewed to determine a last contact date for routine purposes. Those subjects entering the 
Follow-up Period without documented progression will continue to have CT scans in accordance 
&(/*(1
Surviv
Survi
r r th
the End
End
all
all or
or chart
char
are seen 
re seen 
entst
1(35235,(7$5<,1
ncluding bu
ncluding b
if these tes
if these tes
250$7,21
50$
50
)25
1)2
1)
,1
(7$
5,(
35
523
352
( 35
1(
(1(

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
35
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
with standard of care (at least every 90 days) until documented progression of disease, 
withdrawal of consent, lost to follow-up, death or study closure.
&(/*(1(35235,(7$5<,1)250$7,21

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
36
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
7.
STUDY POPULATION
7.1.
Number of Subjects and Sites
Elderly (≥70 years of age) male and female subjects with locally advanced or metastatic NSCLC 
with no prior chemotherapy for metastatic disease will be eligible for this study. The study will 
enroll approximately 284 subjects. The study will be conducted at approximately 65 sites in the 
United States.
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be randomized in the study:
1. Age ≥ 70 years at the time of signing the ICF.
2. Understand and voluntarily provide written informed consent prior to the conduct of any 
study related assessments/procedures.  
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Histologically or cytologically confirmed locally advanced or metastatic NSCLC who are 
not candidates for curative surgery or radiation therapy.
5. No other current active malignancy requiring anticancer therapy.
6. Radiographically documented measurable disease (defined by the presence of 
≥1 radiographically documented measurable lesion).
7. No prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy is 
permitted providing cytotoxic chemotherapy was completed 12 months prior to signing 
the ICF and without disease recurrence.
8. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.
9. Platelets ≥ 100,000 cells/mm3.
10. Hemoglobin (Hgb) ≥ 9 g/dL.
11. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]), alanine
transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × upper limit of 
normal range (ULN) or ≤ 5.0 × ULN if liver metastases.
12. Total bilirubin ≤ 1.5 mg/dL (unless there is a known history of Gilberts Syndrome).
13. Creatinine clearance (CrCl) > 40 mL/min calculated using Cockcroft-Gault equation (if 
renal impairment is suspected 24 hour urine collection for measurement is required).
14. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
15. Females who (1) have undergone hysterectomy (the surgical removal of the uterus) or 
bilateral oophorectomy (the surgical removal of both ovaries) or (2) have been naturally 
postmenopausal for at least 24 consecutive months (ie, has not had menses at any time 
during the preceding 24 consecutive months).
&(/*(1(35235,(7$5<,1)250$7,21
o th
the cond
cond
requiremen
equiremen
ed or meta
ed or meta
py
py.
cancer ther
ancer th
sease (defin
ease (de
ble
ble lesio
lesion)
n
nt of
nt of m
f
eta
eta
motherapy
otherapy w
y
rrence
rrence.
ANC) 
NC) ≥15
1
s/mm
/mm3.
≥ 9 g/dL.
≥ 9 g/dL.
aminase (
aminase (A
e (ALT/seru
ALT/ser
nge (ULN)
nge (ULN)
bili
bilirubin
rubin
i
≤
Creatinine c
atinine 
rena
ren l imp
imp
14.
14. Easte
Easte
15.5. F

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
37
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Male subjects must:
a.
Practice true abstinence* or agree to use a condom during sexual contact with a 
pregnant female or a female of childbearing potential while participating in the study, 
during dose interruptions and for at least 28 days following study drug 
discontinuation, even if he has undergone a successful vasectomy. 
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Evidence of active brain metastases, including leptomeningeal involvement (prior 
evidence of brain metastasis are permitted only if treated and stable and off therapy for
≥4 weeks prior to signing ICF). MRI of the brain (or CT scan w/contrast) is preferred for 
diagnosis.
2. History of leptomeningeal disease.
3. Only evidence of disease is non-measurable.
4. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE v4.0).
5. Venous thromboembolism within 1 month prior to signing ICF.
6. Current congestive heart failure (New York Heart Association Class II-IV).
7. History of the following within 6 months prior to first administration of a study drug: a 
myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass 
graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled 
hypertension, clinically significant cardiac dysrhythmia or clinically significant ECG 
abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.
8. Subject has a known infection with hepatitis B or C, or history of human 
immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or 
myelosuppressive medications that would in the opinion of the investigator, increase the 
risk of serious neutropenic complications.
9. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring 
systemic therapy, defined as ongoing signs/symptoms related to the infection without 
improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
10. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or 
pulmonary hypersensitivity pneumonitis.
11. Treatment with any investigational product within 28 days prior to signing the ICF.
12. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin.
13. Currently enrolled in any other clinical protocol or investigational trial that involves
administration of experimental therapy and/or therapeutic devices.
                                               
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic 
abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable 
methods of contraception].
&(/*(1(352
o
235,(7$5<,1)250$7,21
rapy for
rapy for
preferred
preferred f
TCAE
CAE v4
v4.0
ng ICF.
ng IC
ssociat
sociation n C
o first admi
first adm
a pectoris, c
pectoris
A) Class III
A) Class III
iac dy
ac dysrhy
srhyt
nt,
nt, transi
transien
en
ith
th
i
hepat
hepat
h
iti
V) infect
V) infection
ns that w
ns that w
nic com
nic complic
plic
m
ve, uncontro
e, uncontr
y, defined a
defined
despite app
despite a
i
f ntntersti
erstititi
i a
nary
ary hypers
hype
y
eatme
atmentnt wi
wi
. H
. Hist
is ory
ry o
y
13.
13. Curre
Curr
ad
ad

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
38
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
14. Any other clinically significant medical condition, psychiatric illness, and/or organ 
dysfunction that will interfere with the administration of the therapy according to this 
protocol or which, in the views of investigator, preclude combination chemotherapy.
15. Subject has any other malignancy within 5 years prior to randomization. Exceptions 
include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the 
cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental 
histological finding of prostate cancer (TNM stage of T1a or T1b). All treatment of 
which should have been completed 6 months prior to signing ICF.
16. Any condition including the presence of laboratory abnormalities, which places the 
subject at unacceptable risk if he/she were to participate in the study.
17. Any medical condition that confounds the ability to interpret data from the study.
18. Females who (1) have not undergone hysterectomy (the surgical removal of the uterus) or 
bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been 
naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any 
time during the preceding 24 consecutive months).
&(/*(1(35235,(7$5<,1)250$7,21
study
tudy.
l of
l of the ute
the u
f
have not be
have not b
as had men
as had men

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
39
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Study Drug(s)
Treatment
Subjects will receive open-label nab-paclitaxel and carboplatin during the Treatment Period of 
the study. The nab-paclitaxel and carboplatin are designated as noninvestigational products and 
investigative sites will use standard of care (commercially available) product via prescription.
The preparation for IV administration procedures should be followed as per approved 
Prescribing Information.
8.1.1.
nab-Paclitaxel
Each single-use 50 mL vial contains paclitaxel (100 mg) and approximately 900 mg human 
albumin as a stabilizer.
Unreconstituted nab-paclitaxel should be stored in accordance with the product label. 
Reconstituted nab-paclitaxel should be used immediately. If not used immediately, the vial of 
reconstituted nab-paclitaxel must be placed in its carton and be placed in a refrigerator at 2° to 
8°C (36° to 46°F) for a maximum of 8 hours. Both forms should be stored in an area free of 
environmental extremes and should be accessible only to study personnel.
Temperature records for nab-paclitaxel must be made available to Celgene or other Sponsor-
nominated monitoring teams for verification of proper study drug storage.
8.1.2.
Carboplatin
Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic
agent. The chemical name for carboplatin is platinum diammine [1,1-cyclobutane-
dicarboxylato (2-)-0,0’]-,(SP-4-2). Carboplatin is a crystalline powder with the molecular 
formula of C6Hl2N204Pt and a molecular weight of 371.25. It is soluble in water at a rate of 
approximately 14 mg/mL, and the pH of a 1% solution is 5 to 7. It is virtually insoluble in 
ethanol, acetone, and dimethylacetamide.
For additional information about carboplatin storage, preparation, and administration please refer 
to the package insert. 
8.2.
Treatment Administration and Schedule
Approximately 284 subjects will be treated with nab-paclitaxel plus carboplatin until disease 
progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of 
consent.
Treatment will commence on Day 1, in accordance with standard of care of first-line treatment of 
NSCLC: 
Arm A:
!
nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 
21-day treatment cycle,
&(/*(1(35235,(7$5<,1)250$7,21
n.n.
900 mg hu
900 mg h
y
he product
e produc
used immed
ed immed
e placed in 
placed
ould be sto
ould be sto
study
tudy pers
pe
y
e available 
availab
oper study
oper stud
ompound t
mpound
lat
latinin is plat
is p
Carboplat
Carboplati
molecular w
lecular w
nd
nd th
the p
e pH o
H o
ethylacetam
ethylacetam
atition about
on abo
ert.
rt.
reatment A
atment A
mately
tely 284 
284 
y
ession, deve
ession, deve
sent
sent.
Treatmen
reatmen
NSCLC
NSCLC

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
40
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
!
Carboplatin AUC = 6 mg*min/mL IV on Day 1 of each 21-day treatment cycle, after 
completion of nab-paclitaxel infusion
OR
Arm B:
!
nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8 and 15 of each 
21-day treatment with one-week break cycle (i.e. every 28 days),
!
Carboplatin AUC = 6 mg*min/mL IV on Day 1 of each 21-day treatment with one-
week break cycle (i.e. every 28 days), after completion of nab-paclitaxel infusion.
8.3.
Dose Modifications
Subjects who experience any of the adverse drug reactions in Table 4 will be dose reduced as per 
Table 4 during treatment. 
!
Do not administer nab-paclitaxel on Day 1 of a cycle until ANC is at least 
1500 cells/mm3 and platelet count is at least 100,000 cells/mm3.
!
In subjects who develop severe neutropenia or thrombocytopenia withhold treatment 
until counts recover to an absolute neutrophil count of at least 1500 cells/mm3 and 
platelet count of at least 100,000 cells/mm3 on Day 1 or to an absolute neutrophil 
count of at least 500 cells/mm3 and platelet count of at least 50,000 cells/mm3 on 
Days 8 or 15 of the cycle. Upon resumption of dosing, permanently reduce nab-
paclitaxel and carboplatin doses as outlined in Table 4.
!
Withhold nab-paclitaxel for Grade 3 or 4 peripheral neuropathy. Resume nab-
paclitaxel and carboplatin at reduced doses (Table 4) when peripheral neuropathy 
improves to Grade 1 or completely resolves.
Re-escalation is not permitted at any time. 
&(/*(1(35235,(7$5<,1)250$7,21
n.
e reduc
e reduced
ed
C is at leas
is at lea
mm
mm3
m .
ocytopenia 
cytopenia
of at least 
of at l
ay 1 or to
ay 1 or to a
unt of at l
unt of at le
n of dosing
n of dosing
ned in
ned in Tabl
ab
3 or 4
or 4 perip
peri
uced doses (
ced doses 
etely reso
etely resolvlv
ime.
me.

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
41
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Table 4:
Permanent Dose Reductions for Hematologic and Neurologic Toxicities and Dosing on the Study
Dose Modification During Treatment for A and B arms
Adverse Drug Reaction
Occurrence
nab-Paclitaxel Dose
(mg/m2)
Carboplatin Dose 
(AUC mg*min/mL)
Neutropenic Fever (ANC < 500/mm3 with fever > 38°C)
OR
Delay of next cycle by > 7 days for ANC < 1500/mm3
OR
ANC < 500/mm3 for > 7 days
First
75
4.5
Second
50
3.0
Third
Discontinue Treatment*
Platelet count < 50,000/mm3
First
75
4.5
Second
Discontinue Treatment*
Sensory Neuropathy Grade 3 or 4
First
75
4.5
Second
50
3.0
Third
Discontinue Treatment*
Grade 2 or 3 cutaneous toxicity
Grade 3 diarrhea
Grade 3 mucositis
Any other Grade 3 or 4 nonhematologic toxicity
First
75
4.5
Second
50
3.0
Third
Discontinue Treatment*
Grade 4 cutaneous toxicity, diarrhea or mucositis
First
Discontinue Treatment*
ANC = Absolute Neutrophil Count; AUC = area under the curve.
* If an adverse event that requires dose reduction recurs after the dose has been reduced twice, the subject should generally have treatment discontinued unless, at 
the discretion of the investigator, there is evidence of continuing benefit to the subject that outweighs the risk of recurrent toxicity. Re-Escalation is not 
permitted at anytime.
&(/*(1
pri
prietet
1(35235,(7$
First
First
7$5<,1)250$7,21
e Corpora
e Corpora
21
y
7,2
se
C
$7
0$
5
50
50
)2
,1
< ,
5<
<
cond
ond
$5
7$
Seco
ec
(7
5,(
35
35
35
35
35
3
35
( 3
under the cu
under the 
ion recur
n recurs afaf
evidence of 
evidence of 

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
42
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
8.4.
Method of Treatment Assignment
The Treatment Period of the study is open-label. Enrollment/randomization will occur via IRT 
system for all periods of the study. 
8.5.
Packaging and Labeling
nab-Paclitaxel and carboplatin are designated as noninvestigational products and investigative 
sites will use standard of care (commercially available) product via prescription.
8.6.
Study Drug Accountability and Disposal
nab-Paclitaxel and carboplatin are designated as noninvestigational products and investigative 
sites will use standard of care (commercially available) product via prescription. Procedures for 
proper handling and disposal of anticancer drug must comply with the relevant health, safety and 
environment regulations.
8.7.
Study Drug Compliance
Study drug will be administered only by study site personnel and accurate recording of all study 
drug administration will be made in the appropriate section of the subject’s eCRF and source 
documents.
8.8.
Overdose
Overdose, as defined for this protocol, refers to nab-paclitaxel or carboplatin dosing only.
On a per dose basis, an overdose is defined as 10% over the protocol-specified dose of nab-
paclitaxel or carboplatin given to a subject, regardless of any associated adverse events or 
sequelae. 
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.
On an infusion rate basis, an overdose is defined as any rate faster than the protocol-specified 
rate.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form. See 
Section 11.1 for the reporting of adverse events associated with overdose.
estigative
estigative
rocedures 
ocedures
he
healalth
th
l , s
, saf
accurate rec
ccurate re
the subject’
he sub
b-paclitaxe
paclitaxe
10% over 
10% over 
regardless
regardles
n overdose 
overdos
quency
quency.
overdose i
overdose i
drug admin
drug adm
ental or in
ental or in
the reporti
the report

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
43
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
Over the course of this study, additional medications may be required to manage aspects of the 
disease state of the subjects, including side effects from study treatments or disease recurrence. 
All supportive care (including but not limited to antiemetic medications, white blood cell (WBC)
growth factors, erythrocyte stimulating agents, zolendronic acid, and denosumab) is permitted
and may be administered at the discretion of the investigator, according to local guidelines. 
9.2.
Prohibited Concomitant Medications and Procedures
Other antineoplastic agents or Investigational Product than what is specified in the protocol are 
prohibited.
9.3.
Required Concomitant Medications and Procedures
Not applicable.
&(/*(1(35235,(7$5<,1)250$7,21
)
he protocol
he protoco
ures
ures

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
44
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
10.
STATISTICAL ANALYSES
Statistical analyses for the primary and key secondary endpoints of the study are described 
below.  Additional analyses of these endpoints as well as exploratory endpoints or subgroup 
analyses will be described in detail in the SAP.  The SAP supersedes the analyses described in 
the protocol should there be differences between the two.
10.1.
Overview
Approximately 284 subjects will be randomized in a 1:1 ratio to two treatment arms (142 
subjects per group).  Arm A will receive nab-paclitaxel 100 mg/m2 administered on Days 1, 8 
and 15 followed by carboplatin AUC = 6 mg*min/mL on Day 1 of each 21-day treatment cycle. 
Arm B will receive the same treatment in the same schedule as that of Arm A during the first 21 
days of treatment, but followed by a one-week break prior to the start of next cycle (28-day 
duration). All subjects will receive the assigned study treatment until disease progression, 
unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance of local 
standard of care.  A permuted-block randomization method will be employed, and the 
randomization will be carried out centrally using an IRT system. The randomization will be 
stratified based on the following 2 baseline or prognostic factors:
!
ECOG performance status (0 versus 1)
!
Histology (squamous cell carcinoma versus non-squamous cell carcinoma)
10.2.
Study Population Definitions
10.2.1.
Intent-to-treat Population
The primary efficacy analysis will be performed on the ITT population, which includes all 
randomized subjects regardless of whether the subject receives any study drug or has any 
efficacy assessments performed. 
10.2.2.
Per-protocol (PP) Population
The PP population is defined as all eligible subjects randomized who receive at least one dose of 
the study drug and have been treated in the arm they were assigned to. Additional analyses 
utilizing the PP population will be described in the SAP.
10.2.3.
Treated Population
The treated population will consist of all randomized subjects who receive at least one dose of 
study drug. The treatment groups for the safety analyses will be based on the treatment as 
received if different from the assigned treatment by randomization.
10.3.
Sample Size and Power Considerations
The primary objective of this study is to assess the safety and tolerability of nab-paclitaxel in 
combination with carboplatin administered in 21-day treatment cycles continuously or with a 
&(/*(1(35235,(7$5<,1)250$7,21
2
Day
Days 1, 8
1, 8
eatm
atment cy
ent c
during the f
during th
xt cy
xt cycle
c
(28
(2
ease progre
ase progre
ntnt, in accor
, in acco
emplo
mployed,
yed,
The rando
he rand
ors:
ors:
non
on-squam
squam
s
23
e perform
523
whether 
352
(PP) Popu
(PP) Po
defined as 
defined a
have been
have been
populat
populatio
Treated
Treated P
eated
eated popu
popu
dy drug
drug. Th
. Th
received if 
eceived if
3

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
45
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
one-week break in between cycles for the treatment of locally advanced or metastatic NSCLC in 
elderly subjects (≥ 70 years old). 
The primary study endpoint (also the primary safety endpoint) is the percentage of subjects with 
either peripheral neuropathy of Grade ≥2 or myelosuppression AEs of Grade ≥3 based on the 
local laboratory values for ANC, platelet count, and hemoglobin.  For the purpose of this 
protocol, this endpoint will be referred to as the percentage of subjects with Grade ≥2 peripheral 
neuropathy or Grade ≥3 myelosuppression laboratory adverse events.  
In Protocol CA031, the Phase 3 NSCLC study of the nab-paclitaxel development program, 
approximately 2% of the elderly subjects randomized discontinued from the study prior to 
receiving any study drug.  In addition, approximately 73% of the treated elderly subjects had 
AEs that fell in the category of AEs described above for the primary safety endpoint of the 
current study.  
The study is designed to detect a difference of 16 percentage points between the 2 treatment arms 
with respect to the primary safety endpoint with 80% power and a Type-I error of 5% (two-
sided), assuming the percentage of subjects with the AEs specified above is 73% for Arm A.  
Therefore, the current study is planned to randomize approximately 284 subjects to the 2 
treatment arms in a 1:1 ratio, with the expectation that approximately 278 subjects (139 per 
group) will receive at least one dose of study drug (as observed in CA031) and be included in the 
treated population for the analysis of the primary safety endpoint.
A non-binding interim analysis for futility with the primary safety endpoint will be conducted 
when approximately a total of 139 treated subjects have either completed 6 months of study 
treatment or discontinued from the study due to progression, adverse events, deaths, lost to 
follow up, or other reasons. The stopping rule and the final marginal significance level are 
determined based on the Gamma family spending function with parameter = -7 (Hwang, 1990) to
control the Type-II error rate at 20%. The study may be stopped early for futility if the treatment 
difference is between ± 0.4% (Z-score ± 0.054) given the interim analysis is performed at 50% 
information fraction.  
Progression free survival, OS, and ORR are the key efficacy endpoints of the study.  Since the 
primary research interest of this study is to evaluate the relative safety and toxicities of the 2 
treatment arms, the sample size was calculated based on the primary safety endpoint, the 
percentage of subjects with Grade ≥2 peripheral neuropathy or Grade ≥3 myelosuppression 
laboratory AEs, hence, the study is underpowered for the key efficacy endpoint, PFS, OS and 
ORR.  Consequently, a non-significant treatment difference in PFS, OS or ORR could simply be 
a function of the sample size and/or the lack of statistical power. Therefore, the assessments of 
all efficacy endpoints will be based on the point estimates and the associated 95% confidence 
intervals for the within-group parameters of interest and the between-group differences.  P-
values for between-group comparisons will be provided to indicate the strength of association 
only.  No multiplicity adjustment with the Type-I error rate will be made. 
Of note, based on the data from CA031 it is expected that approximately 67% of the 284
randomized subjects will have a PFS event during the study (i.e. approximately 192 PFS events 
total).  With 192 PFS events, there is 73% power to detect a hazard ratio (HR) of 0.69 for PFS 
improvement with Arm B over Arm A and an overall Type-I error of 5% (two-sided).  Assuming 
&(/
nlyly
(/*(1(35235,(7$5<,1)250$7,21
s had 
s had 
of the
of the
he 2 treatm
he 2 treatm
error of 5%
rror of 5%
ve isis 73
73% f
%
84
84 subject
subjec
elyly 278
78 sub
su
in CA031)
in CA
point.
point.
mary
ary safety
safety
y
y
ave eit
ave e her c
her c
ogressi
ogression, 
on, 
nd the fina
nd the fin
nding funct
nding funct
e study
study m
y
ay
a
± 0.0.054
05 ) g
and ORR ar
nd ORR ar
this study
this stud i
y
e size was 
e size w
with Grade
with Grad
ce, t
e, the stud
he stu
ntntly, a non
ly, a non
he sample 
e sample
endpo
endpoint
ints
for the wi
r the w
s for betwe
s for betw
.  No m
.  No mu
m
Of
Of note, 
note, 
f
ndo
ndo

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
46
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
an exponential distribution with a median time to PFS of 5.8 months for Arm A and proportional 
hazards, a hazard ratio of 0.69 constitutes a 2.6 months improvement for Arm B.  
As an illustration for timeline projection, assuming an exponential distribution for PFS, a 24-
month recruitment period for 284 subjects, and a median PFS of approximately 5.8 months for 
Arm A, it will take approximately 28 months from the first subject randomized to observe 192 
PFS events.
The analysis of both the safety and efficacy endpoints for the clinical study report will be 
performed when approximately 192 PFS events have been observed.  No adjustment for the 
multiple treatment comparisons among the primary and secondary study endpoints will be made.  
Subjects will be followed for OS for at least 6 months after the last subject is randomized or 192 
PFS events have been observed, whichever comes later.
10.4.
Background and Demographic Characteristics
The baseline characteristics of all randomized subjects will be summarized. Subject’s age, 
height, weight, and baseline characteristics will be summarized using descriptive statistics, while 
gender, race and other categorical variables will be provided using frequency tabulations. 
Selected medical history data will be summarized using frequency tabulations by system organ 
class and preferred term.
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both Treatment
and Follow-up Periods. A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
10.6.
Safety Analysis
The treated population, which includes all randomized subjects who received at least one dose of 
study drug, will be the analysis population for all safety analyses.
The safety/tolerability of the two treatment arms will be monitored through continuous reporting 
and evaluated by the primary safety endpoint, adverse events and serious adverse events, 
abnormalities in ANC, platelet count and hemoglobin, and incidence of subjects experiencing 
dose modifications, dose interruptions, and/or premature discontinuation of study drug.
10.6.1.
Primary Safety Endpoint
The primary endpoint for this study is a composite safety endpoint, namely, the percentage of 
subjects who develop either peripheral neuropathy of Grade ≥2 or myelosuppression AEs of 
Grade ≥3 based on the local laboratory values for ANC, platelet count and hemoglobin.  The 
peripheral neuropathy events will be identified from the clinical AE dataset using the 
Standardised MedDRA Queries (SMQs). 
made.
ade.
d or 192
or 192
d. Subject’s
 Subject’s
escript
criptive st
iv
equency tab
quency ta
y tabulat
tabulatioion
ntered, di
ntered, d sc
ing
ing frequen
frequen
enrolled by
enrolled b
ncy tabulat
ncy tabulati
udes all ran
udes all ran
population
population
e two treat
 two trea
mary safet
mary safe
C, platelet c
C, platelet
s, dose inte
, dose inte
rimary Saf
rimary Sa
mary endpoi
endpoi
y
cts
cts who dev
who dev
ade
de ≥3 bas
3 bas
peri
peripheral
pheral
i
l
Standard
Standa

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
47
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
The null (Ho) and alternative (Ha) hypotheses for this endpoint are as follows, where P is the rate 
of the AEs described for the primary safety endpoint: 
Ho:  P Arm B = P Arm A
Ha:  P Arm B ≠ P Arm A
The rate of the AEs described for the primary endpoint will be summarized within each 
treatment schedule by descriptive statistics. The treatment difference in the AE rate will be 
analyzed using a Mantel-Haenszel Chi-square test with ECOG performance status (0 versus 1)
and histology (squamous cell carcinoma versus non-squamous cell carcinoma) as the
stratification factors.  The ratio of the AE rates will be summarized along with the two-sided 
95% confidence interval (CI). 
10.6.2.
Adverse Events
Adverse events will be analyzed in terms of TEAEs, defined as any AE or SAE occurring or 
worsening on or after the first dose of the study drug through 28 days after the last dose of study 
drug.  In addition, any serious AE with an onset date more than 28 days after the last dose of 
study drug that is assessed by the investigator as related to study drug will be considered a 
TEAE. 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). The severity of AEs will be graded based on NCI Common Terminology Criteria 
for Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Treatment-emergent adverse events, Grade 3 or higher TEAEs, serious AEs, TEAEs leading to
dose reduction, dose delay, and dose interruption, TEAEs leading to treatment discontinuation, 
and TEAEs with an outcome of death will be summarized per treatment arms by MedDRA 
system organ class and preferred terms.
Adverse events of special interest of the nab-paclitaxel plus carboplatin combination identified in 
previous studies in a similar population will be summarized in the same manner.
By-subject listings will be provided for all relevant safety data. Graphical displays and figures 
will be provided where useful to assist in the interpretation of results.
10.6.3.
Laboratory Assessments
Hematology Parameters:  In order to investigate the maximal degree of myelosuppression, the 
NCI CTCAE v 4.0 grades for ANC, platelet count, and hemoglobin concentration will be 
summarized by the most severe grade in each treatment cycle and by the most severe grade 
anytime during the study for each treatment arm.  
All other laboratory parameters reported on the eCRFs will be summarized by descriptive 
statistics by visit and treatment if the number of subjects with data is adequate. In addition, NCI 
CTCAE v 4.0 grades for the reported parameters will be summarized, if applicable.  
&(/
yt
(/*(1(35235,(7$5<,1)250$7,21
1)
1)
o-sid
sided 
ed 
r SAE
r SAE occu
after the l
ter the l
f
as
a
day
days after t
s afte
drug will b
drug will 
ict
ictionary
nar f
y f
on NCI Co
on NCI Co
ctronic_app
ronic_app
3 or higher 
3 or higher 
rruption, TE
rruption, T
will be sum
ill be sum
rms.
ms.
est of the
st of the na
na
population
population
be provided
be provid
re useful to
re useful 
rator
ratory As
y As
y Paramete
y Paramete
CAE v
E v 4.0 g
4.0 g
arized by
arized by thth
y
ime durin
ime durin
All other l
All other 
tatist
atistici

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
48
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
10.6.4.
Study Drug Exposure
The extent of exposure to the study drugs will be assessed based on the descriptive statistics on 
the number of cycles and study drug doses administered, cumulative dose, average dose 
intensity, and percentage of protocol dose administered.  The incidences of nab-paclitaxel and/or 
carboplatin dose reductions, dose interruptions, and dose delays will be summarized by treatment 
arm. 
10.7.
Efficacy Analysis
10.7.1.
Key Efficacy Endpoints 
10.7.1.1.
Progression-free Survival
Progression-free survival is defined as the time from the date of randomization to the date of 
disease progression or death (any cause) on or prior to the data cutoff date for analyses, 
whichever occurred first, based on the investigator’s assessment of the data from CT scans using 
RECIST 1.1 guidelines. Baseline tumor measurements will be determined from the radiologic
evaluation performed within 28 days before the start of study therapy.
Subjects who do not have disease progression, or are alive as of the data cutoff date for the 
statistical analysis will be censored at the date of the last radiologic assessment prior to the data 
cutoff date.  Similarly, subjects who discontinue from the study prior to disease progression or 
death will be censored at the date of the last radiologic assessment prior to the data cutoff date.  
In the event that a new anticancer treatment occurs prior to documented progression, the subject 
will be censored at the date of the last radiologic assessment where the subject was documented 
to be progression-free prior to the new anticancer treatment. Subjects with a single missing 
radiologic assessment prior to a visit with documented disease progression (or death) will be 
analyzed as a PFS event at the date of the radiologic assessment that shows progression or death 
(whichever is earlier). Subjects with two or more missing radiologic assessments prior to a visit 
with documented disease progression (or death) will be censored at the date of the last radiologic 
assessment where the subject was documented to be progression-free prior to the first of the two 
missing visits.  Subjects who drop out early or die without any post-baseline radiologic tumor 
assessment will be censored on the date of randomization.
The null (Ho) and alternative (Ha) hypotheses for testing the PFS endpoint are: 
Ho: HR Arm B / Arm A = 1
Ha: HR Arm B / Arm A ≠ 1
Progression-free survival will be summarized using Kaplan-Meier methods with median PFS 
time (including two-sided 95% CI) for each treatment schedule along with the hazard ratio 
estimated using Cox proportional hazards model (including two-sided 95% CI). The Kaplan-
Meier curve for PFS will be presented graphically for each treatment schedule.  P-value from a
stratified log-rank test will be reported as an indication for the strength of association for the 
difference between the two curves, where the strata include ECOG performance status (0 versus 
1) and histology (squamous versus non-squamous cell carcinoma), if the number of events in 
each cell is adequate.  
o the date o
o the date 
r analyses,
r analyses,
a from
from CT 
CT
ed fro
ed from 
m th
y.
the data cu
the data cu
olologig c asse
c ass
study
study pri
pri
y
or
o
assessment
assessmen
prior to doc
rior to do
assessment
assessmen
cer 
er treatm
treatme
ocumented
ocumented
e radi
radiol
ologic
ogic
wo or more
wo or more
on (or deat
n (or dea
as documen
as documen
drop out e
drop out e
d on the d
on the d
rnative (H
rnative (
Arm A
Arm A = 1
= 1
m B / Arm A
Arm A ≠
sion-free su
free s
(including
(including
timated usi
imated usi
Meier curv
Meier curv
tratifie
tratifie

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
49
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
To assess the impact on PFS of radiologic assessments not occurring at the regularly scheduled 
assessment times, the frequency of these unscheduled/off-scheduled assessments will be 
presented for each treatment schedule. In addition, confirmatory and sensitivity analyses will be 
performed to further assess the impact of missed radiologic assessments. An additional analysis 
of PFS, where death or new treatment will be considered as an event, will be conducted to 
address the impact of second-line therapy. 
10.7.1.2.
Overall Survival
Overall survival is defined as the time between randomization and death. All deaths, regardless 
of the cause of death, will be included. All subjects who are lost to follow-up prior to the end of
the study or who are withdrawn from the study will be censored at the time of last contact. 
Subjects who are still receiving treatment as of the data cutoff date will be censored at the cutoff 
date. Overall survival will be analyzed similarly as PFS.
10.7.1.3.
Overall Response Rate 
Overall response rate is defined as the percent of subjects who had a radiologic complete or 
partial response according to RECIST Version 1.1 guidelines determined by the investigator and 
confirmed by repeat radiologic assessment performed no less than 28 days after the criteria for 
response were first met.  
Overall response rate for each treatment arm will be presented with the two-sided 95% CI.  
Relative treatment effect will be summarized by the difference in response rate and the 
associated two-sided 95% CI.  P-value from a Chi-square test will be reported to indicate the 
strength of association of the relative treatment effect.  
10.7.2.
Exploratory Endpoints
10.7.2.1.
Health Care Utilization and Quality of Life Questionnaire
The analysis of health care utilization and quality of life questionnaire data will be described in 
detail in the SAP.
 
10.8.
Study Therapy Termination
Reasons for stopping study therapy will be presented in listings and summarized by frequency of 
occurrence and corresponding percentage of occurrence.
10.9.
Deaths
Deaths reported during treatment (defined as deaths from the first administration of the study 
drug through 28 days post last dose of the study drug) and deaths that occur during the Follow-
up Period will be summarized by frequency of occurrence and corresponding percentage by 
cause of death per period (during treatment or follow-up).
&(/*(1
tudy The
tudy The
for stoppin
stoppin
rence and c
ence and c
10.9.
0.9.
( 35235,(7$5<,1)250$7,21
ess
ess
end of
end of
act.
act
at the cuto
at the cut
dio
diolologigic co
c c
mined by the
ned by th
n 28 day
28 days a
s a
nted with th
nted with t
fference in r
ference in
quare test w
quare test
fect
fect.
nd Quality
d Quality
on and qua
n and qua
Deaths
Deaths
1(3
1(

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
50
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
10.10.
Interim Analysis
A non-binding interim analysis for futility with the primary safety endpoint will be conducted 
when approximately a total of 139 treated subjects have either completed 6 months of study 
treatment or discontinued from the study due to progression, adverse events, deaths, lost to 
follow up, or other reasons. The stopping rule and the final marginal significance level are 
determined based on the Gamma family spending function with parameter = -7 (Hwang, 1990) to 
control the Type-II error rate at 20%. The study may be stopped early for futility if the treatment 
difference is between ± 0.4% (Z-score ± 0.054) given the interim analysis is performed at 50% 
information fraction.
10.11.
Scientific Steering Committee
The conduct of this study will be overseen by a Steering Committee. The Steering Committee 
will serve in an advisory capacity to the Sponsor. 
&(/*(1(35235,(7$5<,1)250$7,21
g Co
Committe
mmitte

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
51
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the subject’s health, 
including laboratory test values (as specified by the criteria in Section 11.3), regardless of 
etiology. Any worsening (ie, any clinically significant adverse change in the frequency or 
intensity of a pre-existing condition) should be considered an AE. A diagnosis or syndrome 
should be recorded on the AE page of the eCRF rather than the individual signs or symptoms of 
the diagnosis or syndrome. 
For the purposes of this study, progressive disease (PD) of NSCLC will not require reporting as 
an adverse event.
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to a study drug should be reported as an AE. If an overdose is 
associated with an AE, the overdose and adverse event should be reported as separate terms. See 
Section 8.8 for the definition of overdose.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for nab-paclitaxel, or 
carboplatin overdose. Actual treatment should depend on the severity of the clinical situation and 
the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study. Assessments may include monitoring of 
any or all of the following parameters: the subject’s clinical symptoms, laboratory, pathological, 
radiological or surgical findings, physical examination findings, or findings from other 
appropriate tests and procedures.
All AEs will be recorded by the investigator from the time the subject signs informed consent to
28 days after the last dose of study drug, and those SAEs made known to the investigator at any 
time thereafter that are suspected of being related to study drug. AEs and serious adverse events 
(SAEs) will be recorded on the AE page of the eCRF and in the subject’s source documents. All 
SAEs must be reported to Celgene Drug Safety within 24 hours of the investigator’s knowledge 
of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
11.2.
Evaluation of Adverse Events
A qualified investigator will evaluate all adverse events as to: 
11.2.1.
Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!
Results in death;
&(/*(1(35235,(7$5<,1)250$7,21
ome
ome
ymptoms of
ymptoms o
equire repor
equire repo
with an AE
with an AE
d as an AE
as an AE
e reported a
eported 
as appropr
as appropr
specific ant
pecific ant
nd on the se
nd on the 
ician.
cian.
g the study
g the study
e subject’s c
subject’s c
cal examin
al examin
invest
investigato
igato
study
study drug
drug
y
spected of b
ected of b
d on the
d on 
AE
A
ted to Cel
ed to Celg
acsimile, or
csimile, or
m.
m.
Evalua
Evalu
ualified 
ualified 
&
inv
inv
11.2.1.
1.2.1.
ser

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
52
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
!
Is life-threatening (ie, in the opinion of the investigator, the subject is at immediate 
risk of death from the AE);
!
Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!
Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);
!
Is a congenital anomaly/birth defect;
!
Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!
A standard procedure for protocol therapy administration. However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!
Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.
!
The administration of blood or platelet transfusion as routine treatment of studied 
indication. However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!
A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling). However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.
!
Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!
A procedure that is planned (ie, planned prior to starting of treatment on study); must 
be documented in the source document and the eCRF. Hospitalization or prolonged 
hospitalization for a complication remains a reportable SAE.
!
An elective treatment of or an elective procedure for a pre-existing condition 
unrelated to the studied indication. 
!
Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.
&(/*(1(35235,(7$5<,1)250$7,21
y life
y life
subject or 
subject or 
ted above.
ted above.
h an AE sho
h an AE sh
on.n Howev
Howev
herapy adm
erapy 
d indicati
indicat
et transfus
t transfusioi
on or prolon
on or prolon
eportable SA
ortable S
isease
ease-rel
relatat
r laboratory
aborator
onged hos
onged hos
le SAE.
le SAE.
n or prolon
n or pro
absence of 
absence of
edure that i
edure that i
ocum
ocumented
ented
ospi
ospitalizati
talizat
i
An elec
An elec
unrel
nr
!
E

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
53
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
For each SAE, the investigator will provide information on severity, start and stop dates, 
relationship to study drug, action taken regarding study drug, and outcome.
11.2.2.
Severity / Intensity
For both AEs and SAEs, the investigator must assess the severity/intensity of the event. 
The severity/intensity of AEs will be graded based upon the subject’s symptoms according to the 
current active minor version of National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE, Version 4.0)
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
Adverse events that are not defined in the NCI CTCAE should be evaluated for severity/intensity 
according to the following scale:
!
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!
Grade 3 = Severe – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!
Grade 4 = Life threatening – extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable
!
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache). This criterion is not the same as “serious” which is based 
on subject/event outcome or action criteria associated with events that pose a threat to a subject’s 
life or functioning.
Seriousness, not severity, serves as a guide for defining regulatory obligations.
11.2.3.
Causality 
The investigator must determine the relationship between the administration of study drug and 
the occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
Means a causal relationship of the adverse event to study drug
administration is unlikely or remote, or other medications, 
therapeutic interventions, or underlying conditions provide a 
sufficient explanation for the observed event.
Suspected:
Means there is a reasonable possibility that the administration 
of study drug caused the adverse event.  ‘Reasonable 
possibility’ means there is evidence to suggest a causal 
relationship between the study drug and the adverse event.
&(/*(1(35235,(7$5<,1)250$7,21
ty/y/int
intensi
ensity
ty
i
vitity;y no m
no me
y,y, som
ome ass
e a
ired
ed
me assistan
e assistan
tio
tion n is poss
s po
on in activi
n in act
therapy
herapy req
req
y
in death
n death
the intens
the intens
ent itself, h
ent itself,
e).
e). This cri
This 
n criteria a
criteria 
serves as a 
rves as a
must determ
must determ
e of an AE/
of an AE
ot suspecte
suspect

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
54
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Causality should be assessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional study 
drug that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
11.2.4.
Duration
For both AEs and SAEs, the investigator will provide a record of the start and stop dates of the 
event.
11.2.5.
Action Taken
The investigator will report the action taken with study drug as a result of an AE or SAE, as 
applicable (eg, discontinuation or reduction of study drug, as appropriate) and report if 
concomitant and/or additional treatments were given for the event. 
11.2.6.
Outcome
The investigator will report the outcome of the event for both AEs and SAEs. All SAEs that have 
not resolved upon discontinuation of the subject’s participation in the study must be followed 
until recovered, recovered with sequelae, not recovered or death (due to the SAE). 
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!
results in discontinuation from the study;
!
requires treatment, modification/ interruption of study drug dose, or any other 
therapeutic intervention; or
!
is judged to be of significant clinical importance.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF. If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.
If possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).
11.4.
Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject or partner of a 
male subject are immediately reportable events.
&(/*(1(35235,(7$5<,1)250$7,21
f the
he
AE or SAE, 
E or SAE
nd report if
nd report i
AEs and SA
Es an
on n in the st
in the s
r death (du
r death (du
be an AE
e an AE if
the study;
he study;
atioion/ interr
n/ inter
or
or
gnificant cl
nificant cl
e, only
, only labo
lab
s a serious
s a serio
mali
ality
ty
i
i
y s o
s o
uld be recor
uld be recor
gnosis or sy
nosis or s
the laborat
the laborat
l ll abor
borator
ato
.4.4.
Pr
Pr
All pregn
All pregn
ale s
ale s

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
55
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
11.4.1.
Female Subjects
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on study drug, or within 3 months 
of the subject’s last dose of study drug, are considered immediately reportable events. Study drug
is to be discontinued immediately. The pregnancy, suspected pregnancy, or positive pregnancy 
test must be reported to Celgene Drug Safety immediately by facsimile, or other appropriate 
method, using the Pregnancy Initial Report Form, or approved equivalent form. The female 
subject should be referred to an obstetrician-gynecologist or another appropriate healthcare 
professional for further evaluation.
The investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the investigator
should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the investigator’s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs. In addition, any infant death after 28 days that the investigator suspects is 
related to the in utero exposure to the study drug should also be reported to Celgene Drug Safety 
by facsimile, or other appropriate method, within 24 hours of the investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2.
Male Subjects
If a female partner of a male subject becomes pregnant while the subject is receiving study drug
or within 3 months of the last dose of study drug, the male subject taking study drug should 
notify the investigator, and the pregnant female partner should be advised to call her healthcare 
provider immediately. If the male subject is receiving study drug, the study drug may need to be 
discontinued in the male subject, but may be resumed later at the discretion of the investigator
and medical monitor.
11.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF. All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the investigator’s knowledge of the event by facsimile, 
or other appropriate method, using the SAE Report Form, or approved equivalent form. This 
instruction pertains to initial SAE reports as well as any follow-up reports.
The investigator is required to ensure that the data on these forms is accurate and consistent. This 
requirement applies to all SAEs (regardless of relationship to study drug) that occur during the 
study (from the time the subject signs informed consent to at least 28 days after the last dose of
study drug) and those made known to the investigator at anytime thereafter that are suspected of 
being related to study drug. SAEs occurring prior to treatment (after signing the ICF) will be 
captured.
&(/*(1(35235,(7$5<,1)250$7,21
mustst
m
norm
normalal or 
or 
l
uivalent for
valent fo
invest
nvestigat
iga
eets any o
ets any of
mile, or othe
le, or o
using the S
using the 
be reported
be reporte
ays that the
s that th
also be rep
lso be re
hours of the
hours of th
uivalent fo
uivalent fo
ome
mes pregn
s pregn
study
study drug
drug
y
gnant fema
ant fema
le subject i
le subject i
ect, but ma
ect, but ma
ing of Ser
ng of Se
eets any crit
ets any cri
eing record
eing record
Drug Safet
ug Safety
r appropria
appropria
ucti
uction pert
on pert
The
The invest
investi
requi
equirem
re
i
dy

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
56
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents. If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available. Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.
Where required by local legislation, the investigator is responsible for informing the Independent 
Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event. The investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail. The response time is expected to be no more than five (5) business 
days. Urgent queries (eg, missing causality assessment) may be handled by phone.
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to nab-paclitaxel based on the Investigator Brochure.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
Celgene or its authorized representative shall notify the investigator of the following 
information: 
!
Any AE suspected of being related to the use of study drug in this study or in other 
studies that is both serious and unexpected (ie, SUSAR);
!
Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC. (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report 
Form/Completion Guidelines or to the Pregnancy Report Form/Completion Guidelines.
&(/*(1(35235,(7$5<,1)250$7,21
e si
e site vi
te vi
i
a a
five (5)
ive (5) bus
b
phone.
phone
determine t
determine
Investigat
nvestigat
rse reaction
se reaction
CFR 312.32
FR 312.
he
he investig
inves
d to the use
d to the use
unexpected
unexpecte
aboratory
aborato
a
y
ng reports o
reports o
atioion, the
n, the ini
pected AE(
pected AE
eep copies 
eep copie
Celgene an
Celgene 
g Safety C
Safety C
ene Drug Sa
e Drug S
Com
ompletet
m
ioion

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
57
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
12.
DISCONTINUATIONS
12.1.
Study Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the study 
drug:
!
Adverse Event(s)
!
Disease progression
!
Withdrawal of consent
!
Death
!
Lost to follow-up
!
Protocol violation
Prior to discontinuing a subject for disease progression, the investigator should contact and 
forward appropriate supporting documents to the Medical Monitor.
All subjects discontinued from study drug for any reason will have a treatment discontinuation 
visit at the time of discontinuation and should undergo treatment discontinuation procedures.
All subjects discontinued from nab-paclitaxel will be followed for a period of 28 days after last
dose of study drug for the collection of AEs.
Additionally subjects who withdraw from or discontinue treatment should be followed for 
progressive disease (if applicable), survival and any new anticancer therapy given.
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.
12.2.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!
Withdrawal of consent
!
Death
!
Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
!
Adverse events(s)
!
Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents. The investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/withdrawn due to an AE (any unacceptable toxicity). All subjects who are 
&(/*(1(35235,(7$5<,1)250$7,21
tor
or shoul
should c
d c
.
have a
ave a trea
t
ment disco
ent disco
llolowed for
wed fo
cont
ontinue
inue tr
nd any
nd any new
new
y
should be r
should be 
uation
uation
onsidered su
nsidered
al o
al of conse
cons
h
ost to follo
ost to follo
owing even
ng eve
y:
!
A

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
58
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
withdrawn from the study should complete all protocol-required evaluations scheduled for early 
termination at the time of withdrawal.
Since follow-up of subjects who discontinue prematurely is of particular importance, every 
attempt should be made to collect all survival information and NSCLC treatment/therapy, unless 
the subject has specifically withdrawn consent from further follow-up. The investigator must 
make every effort to obtain minimal information regarding the subject’s survival status before 
determining that the subject is lost to follow-up.
12.3.
Subject Replacement
Subjects who discontinue will not be replaced.
&(/*(1(35235,(7$5<,1)250$7,21

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
59
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the investigator should contact the responsible Clinical Research
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week. The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/Contract Research 
Organization (CRO) Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
&(/*(1(35235,(7$5<,1)250$7,21
ot be
ot 
ed on
d on
Em
Emergency
ergenc
esponsible
esponsible
ract Resea
ract Resea
nly
nly b
y e used
e used
r or desi
r or design
g

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
60
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative,
and investigator abide by Good Clinical Practice (GCP), as described in International Conference 
on Harmonization (ICH) Guideline E6 and in accordance with the general ethical principles 
outlined in the Declaration of Helsinki. The study will receive approval from an IRB/EC prior to 
commencement. The investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations. Celgene staff or an authorized representative will evaluate and approve all 
investigators who in turn will select their staff.
The investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. 
The investigator should maintain a list of sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.
The investigator is responsible for keeping a record of all subjects who sign an ICF and are 
screened for entry into the study. Subjects who fail screening must have the reason(s) recorded in 
the subject’s source documents.
The investigator, or a designated member of the investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification. The investigator must ensure timely and accurate completion of eCRFs and queries.
14.3.
Subject Information and Informed Consent
The investigator must obtain informed consent of a legal representative prior to any study related 
procedures.
Documentation that informed consent occurred prior to the subject’s entry into the study and of 
the informed consent process should be recorded in the subject’s source documents including the 
date. The original ICF signed and dated by the subject and by the person consenting the subject 
prior to the subject’s entry into the study, must be maintained in the investigator’s study files and 
a copy given to the subject. In addition, if a protocol is amended and it impacts the content of the 
informed consent, the ICF must be revised. Subjects participating in the study when the amended 
protocol is implemented must be re-consented with the revised version of the ICF. The revised
ICF signed and dated by the subject and by the person consenting the subject must be maintained 
in the investigator’s study files and a copy given to the subject.
&(/*(1(35235,(7$5<,1)250$7,21
e
rior to
or to
th
ical Practic
ical Practic
evaluate an
aluate 
study
ud are a
re
study
study-relate
rel
and other 
nd other
dy-
dy-rel
related d
ated
of all subje
of all sub
ail screenin
il screenin
of the
of the inve
inve
ve queries a
queries 
ital charts, 
al charts
st ensure ti
st ensure t
rmation a
mation 
btain
btain infor
fo
that inform
hat inform
consent pr
consent pr
original IC
riginal IC
 the subjec
the subjec
py
py given to
 given to
y
form
formed co
ed co
protocol
protocol il
CF si
CF si

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
61
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibility of the investigator to obtain such permission in 
writing from the appropriate individual.
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor. Amendments will be submitted to the IRB/EC for written approval.
Written approval must be obtained before implementation of the amended version occurs. The 
written signed approval from the IRB/EC should specifically reference the investigator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
This documentation must also include a list of the members of the IRB/EC and their occupation 
and qualifications. If the IRB/EC will not disclose the names, occupations and qualifications of 
the committee members, it should be asked to issue a statement confirming that the composition 
of the committee is in accordance with GCP. For example, the IRB General Assurance Number 
may be accepted as a substitute for this list. Formal approval by the IRB/EC should mention the 
protocol title, number, amendment number (if applicable), study site (or region or area of 
jurisdiction, as applicable), and any other documents reviewed. It must mention the date on 
which the decision was made and must be officially signed by a committee member. Before the 
first subject is enrolled in the study, all ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a coordinating investigator and the IRB/EC. This statement also applies to any 
communication between the investigator (or coordinating investigator, if applicable) and 
regulatory authorities.
&(/*(1(35235,(7$5<,1)250$7,21
arch
arch
or written ap
or written a
versio
version oc
n oc
the invest
inves ig
able. Amen
ble. Ame
be submitt
be submit
dent Ethic
ent Ethi
CF, and
CF, an an
an
or a form 
r a form 
a of jurisdic
of jurisdic
alalso be sub
so be
clude a list 
lude a list
EC will not
EC will no
should be a
hould be
cordance w
cordance
subst
substititutet f
ber, am
ber, amend
end
applicable),
applicable)
cisio
ision was 
n was 
ct is enrolle
enrolle
RB/EC and
RB/EC and
endments i
ndments i
determine w
determine 
he
he inv
inv

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
62
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the investigator must submit to the IRB/EC:
!
Information on serious or unexpected adverse events as soon as possible; 
!
Periodic reports on the progress of the study;
!
Deviations from the protocol or anything that may involve added risk to subjects.
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature discontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!
Unsatisfactory enrollment;
!
GCP noncompliance;
!
Inaccurate or incomplete data collection;
!
Falsification of records;
!
Failure to adhere to the study protocol.
&(/*(1(35235,(7$5<,1)250$7,21
jects.
jects.
medical or 
medical or 
lyly docum
docum
y
en
en
).)
a single sit
a single 
;
rotocol
otocol.

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
63
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The investigator must ensure that the records and documents pertaining to the conduct of the 
study and distribution of the study drug are complete, accurate, filed and retained. Examples of 
source documents include: hospital records; clinic and office charts; laboratory notes; 
memoranda; subject’s diaries or evaluation checklists; dispensing records; recorded data from 
automated instruments; copies or transcriptions certified after verification as being accurate 
copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and the 
laboratories, as well as copies of eCRFs or CD-ROM.
15.2.
Data Management
Data will be entered into the clinical database per Celgene Standard Operating Procedures 
(SOPs). This data will be electronically verified through use of programmed edit checks 
specified by the clinical team. Discrepancies in the data will be brought to the attention of the 
clinical team, and investigational site personnel, if necessary. Resolutions to these issues will be 
reflected in the database. An audit trail within the system will track all changes made to the data.
15.3.
Record Retention
Essential documents must be retained by the investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the study drug. The investigator must retain 
these documents for the time period described above or according to local laws or requirements, 
whichever is longer. Essential documents include, but are not limited to, the following:
!
Signed ICFs for all subjects;
!
Subject identification code list, screening log (if applicable), and enrollment log;
!
Record of all communications between the investigator and the IRB/EC;
!
Composition of the IRB/EC;
!
Record of all communications between the investigator, Celgene, and their authorized 
representative(s);
!
List of sub-investigators and other appropriately qualified persons to whom the 
investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!
Copies of eCRFs (if paper) and of documentation of corrections for all subjects;
!
Study drug accountability records;
!
Record of any body fluids or tissue samples retained;
&(/*(1(35235,(7$5<,1)250$7,21
e
ting Proced
ng Proced
i
med edit ch
ed edit
ght to the at
ht to the a
olut
lu ions to 
ns to
rack all cha
ack al
ator
ator for a m
r a
ion and unt
ion and unt
H region, or 
region, o
ent of the
ent of the sts
ribed above
ribed above
nts include
s include
bjects;
jects
on code lis
n code li
ommu
munica
on of
on of the I
the
f
d of all co
d of all co
presentative
esentativ
List of 
List of su
investi
nvesti
th
the
!

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
64
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
!
All other source documents (subject records, hospital records, laboratory records, 
etc.); 
!
All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.
The investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the investigator is unable to meet this obligation, the investigator must ask Celgene
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21
ities.
ties.
destruction
destruction

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
65
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study. All aspects of the study are reviewed with the investigator and the staff at a study 
initiation visit and/or at an investigator meeting. Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol, eCRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the investigator. Monitoring will 
include on-site visits with the investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone. During monitoring visits, the facilities, 
eCRFs, subject’s source documents, and all other study documentation will be
inspected/reviewed by the Celgene representative in accordance with the Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation. Any resulting 
discrepancies will be reviewed with the investigator and/or his/her staff. Any necessary 
corrections will be made directly to the eCRFs or via queries by the investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified. Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene. Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of subject participation for audits 
and inspections by IRB/IECs, regulatory authorities (eg, FDA, European Medicines Agency 
[EMA], Health Canada) and company authorized representatives. The investigator should make 
every effort to be available for the audits and/or inspections. If the investigator is contacted by 
any regulatory authority regarding an inspection, he/she should contact Celgene immediately.
&(/*(1(35235,(7$5<,1)250$7,21
fter 
ter 
dy
dy
dy
dy, a
, a
nformed 
nformed 
toring will
toring will
ropriate
ropriate
s, the f
, the facili
acili
f
will be
ll be
the Study
the Study
that i
ha s a di
a d
e documen
e docum
his/her sta
his/her st
eries by the
eries by t
onsents, adh
onsents, adh
per recordin
er recordin
y-specific m
specific 
procedures
procedu
entatives o
entatives o
lgene SOP
gene SOP
red to perm
red to pe
CRFs and ap
CRFs and
y IRB/IECs
IRB/IECs
Canada)
Canada) an
to be availa
to be availa
atory
or autho
autho
y

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
66
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes. Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations. Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
67
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
18.
REFERENCES
Azzoli CG, Baker Jr. S, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical 
Oncology clinical practice guideline update on chemotherapy for Stage IV non-small-cell lung 
cancer. J Clin Oncol. 2009;27:6251-66.
Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, et al. Randomized, 
phase III study of weekly paclitaxel in combination with carboplatin versus standard 
every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated 
advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:468-73.
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor 
paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound 
paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 
2006;12(4):1317-24.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer. 2009 Jan;45(2):228-47. 
Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized 
crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer 
Res. 2008;14(13):4200-5. 
Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and 
advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error
probability spending functions. Stat Med. 1990;9:1439-45.
Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, et al. Histamine 
release in dogs by Cremophor El and its derivatives: oxethylated oleic acid is the most effective 
constituent. Agents Actions 1977;7:63-7.
National Institute for Health & Clinical Excellence (NICE): The Diagnosis and Treatment of 
Lung Cancer: Methods, Evidence & Guidance, 2011.
Oken, MM, Creech, RH, Tormey, DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 
1982;5(6):649-55.
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Intergroupe Francophone 
de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared 
with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 
randomised, phase 3 trial. Lancet. 2011;378(9796):1079-88. 
Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, et al. Phase I/II trial of weekly 
intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with Stage IV 
non-small-cell lung cancer. J Clin Oncol. 2008;26(4):639-43.
Schiller JH, Gandara DR, Goss GD, Vokes EE.  Non-small-cell lung cancer: then and now. 
J Clin Oncol. 2013;31(8):981-3.
&(/*(1(35235,(7$5<,1)250$7,21
ated 
ate
intratum
ntratumor
or
n-bound 
-bound 
es
es.
R, Dancey J
Danc
ine (versio
ne (versio
g JB, Desai 
JB, Des
el and nab-
and nab
Crem
Cremopho
op
on. Eur J 
Eur J C
uential desi
uential desi
1990;9:143
1990;9:143
ormann P, 
ormann P, 
nd its deriv
d its deriv
7;7:63
7;7:63-7.
-7.
& Clinical
& Clinic
Evidence &
Evidenc
RH, Torme
RH, Torm
Of The Ea
Of The Ea
55.
55.
alcman G, 
alcman G, 
érologie Th
érologie T
monotherap
onother
ndo
domised, 
mised, 
Ri
Rizvi NA
zvi NA
rav
ra

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
68
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, et al. Safety and efficacy of 
weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients 
with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(2):314-21. 
Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, et al. A 
dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as 
first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 
2010;5(6):852-61.
Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. 
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical 
pharmacokinetic implications. Cancer Res. 1999;59(7):1454-7.
Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation 
vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665-85. 
Review.
Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. Rapid 
esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of 
docetaxel and metabolites in mice. Clin Cancer Res. 1999;5(10):2918-24.
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. 
Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8(7):1263-8.
&(/*(1(35235,(7$5<,1)250$7,21
latatioion
):665
):665-85.
85
Sparreboom
parreboom
lasma phar
asma pha
18-24.
-24.
Trump DL
Trump DL
(7):1263
(7):1263-8.
-8

nab-paclitaxel
Protocol ABI-007-NSCL-005
Celgene Corporation
Confidential and Proprietary
69
ABI-007-NSCL-005 Amendment 1.0 Final: 09 Apr 2014
19.
APPENDICES
Appendix A: ECOG Performance Status Score
Grade
ECOG
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up 
and about more than 50% of waking hours
3
Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours
4
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5
Dead
Oken, 1982.
&(/*(1(35235,(7$5<,1)
han 50% of 
an 50% of
1)250$7,21
0$
rk of a 
rk of a 
0$
0$
0$
ctivities. Up
ctivities. Up
25
1)
ally confined
ally confine
<
$5
7$

Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH

7LWOH

'DWH7KXUVGD\$SULO30(DVWHUQ'D\OLJKW7LPH
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\